Monoclonal Antibodies Market by Source (Murine, Chimeric, Humanized, Human) by Type (Naked Monoclonal Antibodies, Conjugated Monoclonal Antibodies, Bispecific Monoclonal Antibodies, Others) by Clinical Trial Phases (Phase 0, Phase I, Phase II, Phase III, Phase IV) by Source (Diagnostic Testing, Autoimmune Diseases, Cancer Treatment (Breast Cancer, Stomach Cancer, Others) Pregnancy Testing, Radioimmunodetection (RID) of Cancer, Radioimmunotheraphy (RIT) of Cancer, Viral Disease Treatment, Identifying Pathogens, Alzheimer’s disease, Chronic Lymphocytic Leukemia and Non-Hodgkin’s Lymphoma, Rhesus Disease Immunization, Systemic Lupus Erythematosus, Crohn's Disease, Ulcerative Colitis, Psoriasis and Rheumatoid Arthritis, Cardiovascular Disease, Others) by End Use (Hospitals, Clinics, Research Institutes, Others); By Region (U.S., Canada, Mexico, Rest of North America, France, UK, Germany, Spain, Italy, Nordic Countries, Benelux Union, Rest of Europe, China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia, Rest of Asia Pacific, Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of MEA, Brazil, Argentina, Rest of Latin America) – Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2020 - 2028
Industry Trends
Global monoclonal antibodies market was valued at US$ 123.65 billion in 2020 and is expected to reach US$ 239.01 billion by 2028, growing at a CAGR of 13.1% over the forecast period. Monoclonal antibodies are proteins in the immune system that are produced in laboratories. In cancer therapy, clinical techniques associated with monoclonal antibodies are used. In the coming years developments in ongoing clinical trials of medications as well as treatment choices related to these drugs will support the growth of the overall market. Growing investment in product research and development would have a positive impact in the coming years on the growth of the overall market. Monoclonal antibodies are composed of identical antibody molecules and are formed by a single cell clone or cell line. In the pharmaceutical and biotechnology fields monoclonal antibodies have brought about a revolutionary shift and are also expected to play a critical role in the future. The global market for monoclonal antibodies is characterised by the emergence and diverse presence of numerous global and regional players. On the basis of technology, cost and product differentiation the players compete with the local ones.
The rising prevalence of cancer and other chronic illnesses is driving the growth of the global market for monoclonal antibodies. Such diseases have contributed to an increase in demand for biologics, contributing in turn to the demand for monoclonal antibodies. In addition to the advent of technologically advanced genetic platforms such as next-generation sequencing rising pressure on research and development activities in genomics has also added significantly to the sector. Moreover the affordability of the technology needed to build mAbs for research has also contributed to market development. Other factors that have a positive effect on the market include increasing patient and physician understanding of mAb therapy applications. The use of therapeutic antibodies in cost-sensitive markets, and rapid approval of breakthrough therapies by regulatory authorities will boost the market growth.
Increased approval by regulatory agencies of monoclonal antibodies favors the launch of new therapeutics, which is expected to fuel market growth over the forecast period. Chugai Pharmaceutical Co., Ltd. announced in 2018 that it won the U.S. Breakthrough Therapy Designation FDA, for its Satralizumabab offering, Johnson & Johnson also won in May 2018. Monoclonal antibodies offer major opportunities because, unlike chemotherapy medications, they are targeted therapy. It results in decreased side effects and improved efficacy. The growth of the monoclonal antibody market is driven by increased research & development by prominent players. Mergers, acquisitions, and new product launches were some of the key strategies followed by the players operating in the global monoclonal antibody market.
Rising levels of understanding among patients and doctors of mAb therapy applications are leading to further development. In addition the approval of blockbuster mAbs for a variety of indications is projected to increase the use rates. For example, major revenue-generating medications with FDA approval for a range of conditions (cancer, rheumatoid arthritis, Crohn's disease, ulcerative colitis, etc.) such as Avastin, Herceptin, Remicade, and Rituxan further improve the patient base. Due to the existence of a large product pipeline, this market is projected to expand at a lucrative CAGR over the forecast period. There are generally recognized biologics and are projected to provide pharmaceutical manufacturers with a billion-dollar opportunity over the forecast era.
Primary market developments include growing cancer incidence, increasing regulatory approvals and the launch of treatments, increasing research partnerships to build a comprehensive drug pipeline and the adoption of collaborative strategies by companies. Demand for these therapies is projected to increase the incidence of cancer thus leading to a substantial rise in the demand for monoclonal antibodies. For example, in 2018 breast cancer accounted for the second highest number of cancer cases worldwide accounting for 2,088,849 new cases worldwide in 2018 according to the World Cancer Research Fund International's report. In addition, a major factor expected to drive market growth over the forecast period is growing research collaborations for the production of a robust drug pipeline. Market growth is expected to be guided by a growing number of product approvals.
Investments in the production of novel monoclonal antibodies are being made by several pharmaceuticals, biotech firms, universities and cancer centers. Several monoclonal antibodies have been launched in the market such as immune-checkpoint inhibitors, immuno-oncology drugs and others, contributing significantly to market development.
However, the high cost of monoclonal antibody therapy makes it unaffordable for the low- and middle-income population to opt for these therapies which in turn hampers business growth. It is also predicted that the lack of patents will hinder business growth over the projected period. For example, in the U.S. and Europe, Genentech, Inc. (RocheRituximab)'s (Rituxan) product lost its patent.
Market development is expected to be favored by a growing number of government programs and support for clinical trials of drugs that can be used in the Covid-19 treatment. For example, the World Health Organization initiated the 'Solidarity' trial in March 2020, which is a global effort to test old and new drugs/therapies for Covid-19 care. In recent times, the growing investment in product research and development has produced a few exceptional products. Companies are designing new drugs that help cure diseases and aids to combat serious diseases such as cancer and coronavirus.
Source Insights
Due to its wide use in the treatment of different diseases, including cancer, inflammatory, and autoimmune diseases, Humanized mAbs accounted for the largest revenue share in the market over the forecast period. Furthermore, the advanced genetic engineering technology used in its development is a possible driver of growth for this segment. The segment of human antibodies has been increasing rapidly due to the incorporation of advanced technologies for their generation, such as phage or yeast display and transgenic mice.
Type Insights
In type the naked monoclononal antibodies segment dominated the market over the forecast period. Naked mAbs are antibodies that do not have any attached drug or harmful material. These are the most common form of mAbs for cancer treatment.
Clinical Trial Phases Insights
Market growth is expected to be guided by a growing number of product approvals. During the forecast period adoption of collaborative strategies by key market players is expected to drive market growth. There are many drugs in the pipeline which are in phase II and III.
Application Insights
MAbs have wide uses in the treatment of cancer. In addition, the surging incidence of cancer is the main contributing factor to the growth of mAbs. Compared to medications and chemotherapy these have proved to be the safest treatment choice for cancer due to the limited adverse effects associated with their use. In addition, many products are undergoing clinical trials and the growing drug pipeline is therefore expected to provide this vertical with potential growth opportunities.
End Use Insights
Increased acceptance of mAbs as the preferred treatment line, especially in the case of cancer, contributed to the largest share in the hospital segment. Factors that are expected to result in the dominance of hospitals in the end-use segment during the forecast period are the growing prevalence of chronic conditions, rising healthcare expenditure level, and knowledge level among the patient population about treatment alternatives.
Regional Insights
Because of the existence of a well-established healthcare system, North America held the highest share over the years. In addition, increased government support for cancer research and technology advancement over the projected period is expected to accelerate the development of therapeutic proteins. Other significant factors promoting the growth of this sector are government funding for infection prevention & management, the prevalence of lifestyle-associated diseases, and increasing population numbers.
Monoclonal Antibodies Market Revenue & Forecast, (US$ Million), 2020 – 2028
Competitive Landscape
The report provides both, qualitative and quantitative research monoclonal antibodies market, as well as provide comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contacts adopted by these major market participants are also recognized and analysed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.
The major players operating in the market include Amgen Inc., Bristol-Myers Squibb Company, DAIICHI SANKYO COMPANY, LIMITED., Eli Lilly & Co. (acquired ImClone Systems, Inc.), F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc., Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis AG, Pfizer Inc. and other market participants.
Monoclonal Antibodies Market:
- By Source
- Murine
- Chimeric
- Humanized
- Human
- By Type
- Naked Monoclonal Antibodies
- Conjugated Monoclonal Antibodies
- Bispecific Monoclonal Antibodies
- Others
- By Clinical Trial Phases
- Phase 0
- Phase I
- Phase II
- Phase III
- Phase IV
- By Application
- Diagnostic Testing
- Autoimmune Diseases
- Cancer Treatment
- Breast Cancer
- Stomach Cancer
- Others
- Pregnancy Testing
- Radioimmunodetection (RID) of Cancer
- Radioimmunotheraphy (RIT) of Cancer
- Viral Disease Treatment
- Identifying Pathogens
- Alzheimer’s disease
- Chronic Lymphocytic Leukemia and Non-Hodgkin’s Lymphoma
- Rhesus Disease Immunization
- Systemic Lupus Erythematosus
- Crohn's Disease
- Ulcerative Colitis
- Psoriasis and Rheumatoid Arthritis
- Cardiovascular Disease
- Others
- By End Use
- Hospitals
- Clinics
- Research Institutes
- Others
- By Region:
- North America
- U.S.
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
- North America
Table of Contents
1. Market
Scope
1.1. Market
Segmentation
1.2. Years
Considered
1.2.1. Historic
Years: 2015 - 2018
1.2.2. Base
Year: 2019
1.2.3. Forecast
Years: 2020 – 2028
2. Key Target
Audiences
3. Research
Methodology
3.1. Primary
Research
3.1.1. Research
Questionnaire
3.1.2. Global
Percentage Breakdown
3.1.3. Primary
Interviews: Key Opinion Leaders (KOLs)
3.2. Secondary
Research
3.2.1. Paid
Databases
3.2.2. Secondary
Sources
3.3. Market
Size Estimates
3.3.1. Top-Down
Approach
3.3.2. Bottom-Up
Approach
3.4. Data
Triangulation Methodology
3.5. Research
Assumptions
4. Recommendations
and Insights from AMI’s Perspective**
5. Holistic
Overview of Monoclonal Antibodies Market
6. Market
Synopsis: Monoclonal Antibodies Market
7. Monoclonal
Antibodies Market Analysis: Qualitative Perspective
7.1. Introduction
7.1.1. Product
Definition
7.1.2. Industry
Development
7.2. Market
Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.3. Trends in
Monoclonal Antibodies Market
7.4. Market
Determinants Radar Chart
7.5. Macro-Economic
and Micro-Economic Indicators: Monoclonal Antibodies Market
7.6. Porter’s Five Force Analysis
7.7. Impact of
Covid-19 on Monoclonal Antibodies Market
8. Global
Monoclonal Antibodies Market Analysis and Forecasts, 2020 – 2028
8.1. Overview
8.1.1. Global
Monoclonal Antibodies Market Revenue (US$ Mn)
8.2. Global
Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Source
8.2.1. Murine
8.2.1.1. Definition
8.2.1.2. Market
Estimation and Penetration, 2015 – 2019
8.2.1.3. Market
Forecast, 2020 – 2028
8.2.1.4. Compound
Annual Growth Rate (CAGR)
8.2.1.5. Regional
Bifurcation
8.2.1.5.1. North
America
8.2.1.5.1.1. Market
Estimation, 2015 – 2019
8.2.1.5.1.2. Market
Forecast, 2020 – 2028
8.2.1.5.2. Europe
8.2.1.5.2.1. Market
Estimation, 2015 – 2019
8.2.1.5.2.2. Market
Forecast, 2020 – 2028
8.2.1.5.3. Asia
Pacific
8.2.1.5.3.1. Market
Estimation, 2015 – 2019
8.2.1.5.3.2. Market
Forecast, 2020 – 2028
8.2.1.5.4. Middle
East and Africa
8.2.1.5.4.1. Market
Estimation, 2015 – 2019
8.2.1.5.4.2. Market
Forecast, 2020 – 2028
8.2.1.5.5. Latin
America
8.2.1.5.5.1. Market
Estimation, 2015 – 2019
8.2.1.5.5.2. Market
Forecast, 2020 – 2028
8.2.2. Chimeric
8.2.2.1. Definition
8.2.2.2. Market
Estimation and Penetration, 2015 – 2019
8.2.2.3. Market
Forecast, 2020 – 2028
8.2.2.4. Compound
Annual Growth Rate (CAGR)
8.2.2.5. Regional
Bifurcation
8.2.2.5.1. North
America
8.2.2.5.1.1. Market
Estimation, 2015 – 2019
8.2.2.5.1.2. Market
Forecast, 2020 – 2028
8.2.2.5.2. Europe
8.2.2.5.2.1. Market
Estimation, 2015 – 2019
8.2.2.5.2.2. Market
Forecast, 2020 – 2028
8.2.2.5.3. Asia
Pacific
8.2.2.5.3.1. Market
Estimation, 2015 – 2019
8.2.2.5.3.2. Market
Forecast, 2020 – 2028
8.2.2.5.4. Middle
East and Africa
8.2.2.5.4.1. Market
Estimation, 2015 – 2019
8.2.2.5.4.2. Market
Forecast, 2020 – 2028
8.2.2.5.5. Latin
America
8.2.2.5.5.1. Market
Estimation, 2015 – 2019
8.2.2.5.5.2. Market
Forecast, 2020 – 2028
8.2.3. Humanized
8.2.3.1. Definition
8.2.3.2. Market
Estimation and Penetration, 2015 – 2019
8.2.3.3. Market
Forecast, 2020 – 2028
8.2.3.4. Compound
Annual Growth Rate (CAGR)
8.2.3.5. Regional
Bifurcation
8.2.3.5.1. North
America
8.2.3.5.1.1. Market
Estimation, 2015 – 2019
8.2.3.5.1.2. Market
Forecast, 2020 – 2028
8.2.3.5.2. Europe
8.2.3.5.2.1. Market
Estimation, 2015 – 2019
8.2.3.5.2.2. Market
Forecast, 2020 – 2028
8.2.3.5.3. Asia
Pacific
8.2.3.5.3.1. Market
Estimation, 2015 – 2019
8.2.3.5.3.2. Market
Forecast, 2020 – 2028
8.2.3.5.4. Middle
East and Africa
8.2.3.5.4.1. Market
Estimation, 2015 – 2019
8.2.3.5.4.2. Market
Forecast, 2020 – 2028
8.2.3.5.5. Latin
America
8.2.3.5.5.1. Market
Estimation, 2015 – 2019
8.2.3.5.5.2. Market
Forecast, 2020 – 2028
8.2.4. Human
8.2.4.1. Definition
8.2.4.2. Market
Estimation and Penetration, 2015 – 2019
8.2.4.3. Market
Forecast, 2020 – 2028
8.2.4.4. Compound
Annual Growth Rate (CAGR)
8.2.4.5. Regional
Bifurcation
8.2.4.5.1. North
America
8.2.4.5.1.1. Market
Estimation, 2015 – 2019
8.2.4.5.1.2. Market
Forecast, 2020 – 2028
8.2.4.5.2. Europe
8.2.4.5.2.1. Market
Estimation, 2015 – 2019
8.2.4.5.2.2. Market
Forecast, 2020 – 2028
8.2.4.5.3. Asia
Pacific
8.2.4.5.3.1. Market
Estimation, 2015 – 2019
8.2.4.5.3.2. Market
Forecast, 2020 – 2028
8.2.4.5.4. Middle
East and Africa
8.2.4.5.4.1. Market
Estimation, 2015 – 2019
8.2.4.5.4.2. Market
Forecast, 2020 – 2028
8.2.4.5.5. Latin
America
8.2.4.5.5.1. Market
Estimation, 2015 – 2019
8.2.4.5.5.2. Market
Forecast, 2020 – 2028
8.3. Key
Segment for Channeling Investments
8.3.1. By
Source
9. Global
Monoclonal Antibodies Market Analysis and Forecasts, 2020 – 2028
9.1. Overview
9.2. Global
Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Type
9.2.1. Naked
Monoclonal Antibodies
9.2.1.1. Definition
9.2.1.2. Market
Estimation and Penetration, 2015 – 2019
9.2.1.3. Market
Forecast, 2020 – 2028
9.2.1.4. Compound
Annual Growth Rate (CAGR)
9.2.1.5. Regional
Bifurcation
9.2.1.5.1. North
America
9.2.1.5.1.1. Market
Estimation, 2015 – 2019
9.2.1.5.1.2. Market
Forecast, 2020 – 2028
9.2.1.5.2. Europe
9.2.1.5.2.1. Market
Estimation, 2015 – 2019
9.2.1.5.2.2. Market
Forecast, 2020 – 2028
9.2.1.5.3. Asia
Pacific
9.2.1.5.3.1. Market
Estimation, 2015 – 2019
9.2.1.5.3.2. Market
Forecast, 2020 – 2028
9.2.1.5.4. Middle
East and Africa
9.2.1.5.4.1. Market
Estimation, 2015 – 2019
9.2.1.5.4.2. Market
Forecast, 2020 – 2028
9.2.1.5.5. Latin
America
9.2.1.5.5.1. Market
Estimation, 2015 – 2019
9.2.1.5.5.2. Market
Forecast, 2020 – 2028
9.2.2. Conjugated
Monoclonal Antibodies
9.2.2.1. Definition
9.2.2.2. Market
Estimation and Penetration, 2015 – 2019
9.2.2.3. Market
Forecast, 2020 – 2028
9.2.2.4. Compound
Annual Growth Rate (CAGR)
9.2.2.5. Regional
Bifurcation
9.2.2.5.1. North
America
9.2.2.5.1.1. Market
Estimation, 2015 – 2019
9.2.2.5.1.2. Market
Forecast, 2020 – 2028
9.2.2.5.2. Europe
9.2.2.5.2.1. Market
Estimation, 2015 – 2019
9.2.2.5.2.2. Market
Forecast, 2020 – 2028
9.2.2.5.3. Asia
Pacific
9.2.2.5.3.1. Market
Estimation, 2015 – 2019
9.2.2.5.3.2. Market
Forecast, 2020 – 2028
9.2.2.5.4. Middle
East and Africa
9.2.2.5.4.1. Market
Estimation, 2015 – 2019
9.2.2.5.4.2. Market
Forecast, 2020 – 2028
9.2.2.5.5. Latin
America
9.2.2.5.5.1. Market
Estimation, 2015 – 2019
9.2.2.5.5.2. Market
Forecast, 2020 – 2028
9.2.3. Bispecific
Monoclonal Antibodies
9.2.3.1. Definition
9.2.3.2. Market
Estimation and Penetration, 2015 – 2019
9.2.3.3. Market
Forecast, 2020 – 2028
9.2.3.4. Compound
Annual Growth Rate (CAGR)
9.2.3.5. Regional
Bifurcation
9.2.3.5.1. North
America
9.2.3.5.1.1. Market
Estimation, 2015 – 2019
9.2.3.5.1.2. Market
Forecast, 2020 – 2028
9.2.3.5.2. Europe
9.2.3.5.2.1. Market
Estimation, 2015 – 2019
9.2.3.5.2.2. Market
Forecast, 2020 – 2028
9.2.3.5.3. Asia
Pacific
9.2.3.5.3.1. Market
Estimation, 2015 – 2019
9.2.3.5.3.2. Market
Forecast, 2020 – 2028
9.2.3.5.4. Middle
East and Africa
9.2.3.5.4.1. Market
Estimation, 2015 – 2019
9.2.3.5.4.2. Market
Forecast, 2020 – 2028
9.2.3.5.5. Latin
America
9.2.3.5.5.1. Market
Estimation, 2015 – 2019
9.2.3.5.5.2. Market
Forecast, 2020 – 2028
9.2.4. Others
9.2.4.1. Definition
9.2.4.2. Market
Estimation and Penetration, 2015 – 2019
9.2.4.3. Market
Forecast, 2020 – 2028
9.2.4.4. Compound
Annual Growth Rate (CAGR)
9.2.4.5. Regional
Bifurcation
9.2.4.5.1. North
America
9.2.4.5.1.1. Market
Estimation, 2015 – 2019
9.2.4.5.1.2. Market
Forecast, 2020 – 2028
9.2.4.5.2. Europe
9.2.4.5.2.1. Market
Estimation, 2015 – 2019
9.2.4.5.2.2. Market
Forecast, 2020 – 2028
9.2.4.5.3. Asia
Pacific
9.2.4.5.3.1. Market
Estimation, 2015 – 2019
9.2.4.5.3.2. Market
Forecast, 2020 – 2028
9.2.4.5.4. Middle
East and Africa
9.2.4.5.4.1. Market
Estimation, 2015 – 2019
9.2.4.5.4.2. Market
Forecast, 2020 – 2028
9.2.4.5.5. Latin
America
9.2.4.5.5.1. Market
Estimation, 2015 – 2019
9.2.4.5.5.2. Market
Forecast, 2020 – 2028
9.3. Key
Segment for Channeling Investments
9.3.1. By Type
10. Global
Monoclonal Antibodies Market Analysis and Forecasts, 2020 – 2028
10.1. Overview
10.2. Global
Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Clinical Trial
Phases
10.2.1. Phase 0
10.2.1.1. Definition
10.2.1.2. Market
Estimation and Penetration, 2015 – 2019
10.2.1.3. Market
Forecast, 2020 – 2028
10.2.1.4. Compound
Annual Growth Rate (CAGR)
10.2.1.5. Regional
Bifurcation
10.2.1.5.1. North
America
10.2.1.5.1.1. Market
Estimation, 2015 – 2019
10.2.1.5.1.2. Market
Forecast, 2020 – 2028
10.2.1.5.2. Europe
10.2.1.5.2.1. Market
Estimation, 2015 – 2019
10.2.1.5.2.2. Market
Forecast, 2020 – 2028
10.2.1.5.3. Asia
Pacific
10.2.1.5.3.1. Market
Estimation, 2015 – 2019
10.2.1.5.3.2. Market
Forecast, 2020 – 2028
10.2.1.5.4. Middle
East and Africa
10.2.1.5.4.1. Market
Estimation, 2015 – 2019
10.2.1.5.4.2. Market
Forecast, 2020 – 2028
10.2.1.5.5. Latin
America
10.2.1.5.5.1. Market
Estimation, 2015 – 2019
10.2.1.5.5.2. Market
Forecast, 2020 – 2028
10.2.2. Phase I
10.2.2.1. Definition
10.2.2.2. Market
Estimation and Penetration, 2015 – 2019
10.2.2.3. Market
Forecast, 2020 – 2028
10.2.2.4. Compound
Annual Growth Rate (CAGR)
10.2.2.5. Regional
Bifurcation
10.2.2.5.1. North
America
10.2.2.5.1.1. Market
Estimation, 2015 – 2019
10.2.2.5.1.2. Market
Forecast, 2020 – 2028
10.2.2.5.2. Europe
10.2.2.5.2.1. Market
Estimation, 2015 – 2019
10.2.2.5.2.2. Market
Forecast, 2020 – 2028
10.2.2.5.3. Asia
Pacific
10.2.2.5.3.1. Market
Estimation, 2015 – 2019
10.2.2.5.3.2. Market
Forecast, 2020 – 2028
10.2.2.5.4. Middle
East and Africa
10.2.2.5.4.1. Market
Estimation, 2015 – 2019
10.2.2.5.4.2. Market
Forecast, 2020 – 2028
10.2.2.5.5. Latin
America
10.2.2.5.5.1. Market
Estimation, 2015 – 2019
10.2.2.5.5.2. Market
Forecast, 2020 – 2028
10.2.3. Phase
II
10.2.3.1. Definition
10.2.3.2. Market
Estimation and Penetration, 2015 – 2019
10.2.3.3. Market
Forecast, 2020 – 2028
10.2.3.4. Compound
Annual Growth Rate (CAGR)
10.2.3.5. Regional
Bifurcation
10.2.3.5.1. North
America
10.2.3.5.1.1. Market
Estimation, 2015 – 2019
10.2.3.5.1.2. Market
Forecast, 2020 – 2028
10.2.3.5.2. Europe
10.2.3.5.2.1. Market
Estimation, 2015 – 2019
10.2.3.5.2.2. Market
Forecast, 2020 – 2028
10.2.3.5.3. Asia
Pacific
10.2.3.5.3.1. Market
Estimation, 2015 – 2019
10.2.3.5.3.2. Market
Forecast, 2020 – 2028
10.2.3.5.4. Middle
East and Africa
10.2.3.5.4.1. Market
Estimation, 2015 – 2019
10.2.3.5.4.2. Market
Forecast, 2020 – 2028
10.2.3.5.5. Latin
America
10.2.3.5.5.1. Market
Estimation, 2015 – 2019
10.2.3.5.5.2. Market
Forecast, 2020 – 2028
10.2.4. Phase
III
10.2.4.1. Definition
10.2.4.2. Market
Estimation and Penetration, 2015 – 2019
10.2.4.3. Market
Forecast, 2020 – 2028
10.2.4.4. Compound
Annual Growth Rate (CAGR)
10.2.4.5. Regional
Bifurcation
10.2.4.5.1. North
America
10.2.4.5.1.1. Market
Estimation, 2015 – 2019
10.2.4.5.1.2. Market
Forecast, 2020 – 2028
10.2.4.5.2. Europe
10.2.4.5.2.1. Market
Estimation, 2015 – 2019
10.2.4.5.2.2. Market
Forecast, 2020 – 2028
10.2.4.5.3. Asia
Pacific
10.2.4.5.3.1. Market
Estimation, 2015 – 2019
10.2.4.5.3.2. Market
Forecast, 2020 – 2028
10.2.4.5.4. Middle
East and Africa
10.2.4.5.4.1. Market
Estimation, 2015 – 2019
10.2.4.5.4.2. Market
Forecast, 2020 – 2028
10.2.4.5.5. Latin
America
10.2.4.5.5.1. Market
Estimation, 2015 – 2019
10.2.4.5.5.2. Market
Forecast, 2020 – 2028
10.2.5. Phase
IV
10.2.5.1. Definition
10.2.5.2. Market
Estimation and Penetration, 2015 – 2019
10.2.5.3. Market
Forecast, 2020 – 2028
10.2.5.4. Compound
Annual Growth Rate (CAGR)
10.2.5.5. Regional
Bifurcation
10.2.5.5.1. North
America
10.2.5.5.1.1. Market
Estimation, 2015 – 2019
10.2.5.5.1.2. Market
Forecast, 2020 – 2028
10.2.5.5.2. Europe
10.2.5.5.2.1. Market
Estimation, 2015 – 2019
10.2.5.5.2.2. Market
Forecast, 2020 – 2028
10.2.5.5.3. Asia
Pacific
10.2.5.5.3.1. Market
Estimation, 2015 – 2019
10.2.5.5.3.2. Market
Forecast, 2020 – 2028
10.2.5.5.4. Middle
East and Africa
10.2.5.5.4.1. Market
Estimation, 2015 – 2019
10.2.5.5.4.2. Market
Forecast, 2020 – 2028
10.2.5.5.5. Latin
America
10.2.5.5.5.1. Market
Estimation, 2015 – 2019
10.2.5.5.5.2. Market
Forecast, 2020 – 2028
10.3. Key
Segment for Channeling Investments
10.3.1. By
Clinical Trial Phases
11. Global
Monoclonal Antibodies Market Analysis and Forecasts, 2020 – 2028
11.1. Overview
11.2. Global
Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Application
11.2.1. Diagnostic
Testing
11.2.1.1. Definition
11.2.1.2. Market
Estimation and Penetration, 2015 – 2019
11.2.1.3. Market
Forecast, 2020 – 2028
11.2.1.4. Compound
Annual Growth Rate (CAGR)
11.2.1.5. Regional
Bifurcation
11.2.1.5.1. North
America
11.2.1.5.1.1. Market
Estimation, 2015 – 2019
11.2.1.5.1.2. Market
Forecast, 2020 – 2028
11.2.1.5.2. Europe
11.2.1.5.2.1. Market
Estimation, 2015 – 2019
11.2.1.5.2.2. Market
Forecast, 2020 – 2028
11.2.1.5.3. Asia
Pacific
11.2.1.5.3.1. Market
Estimation, 2015 – 2019
11.2.1.5.3.2. Market
Forecast, 2020 – 2028
11.2.1.5.4. Middle
East and Africa
11.2.1.5.4.1. Market
Estimation, 2015 – 2019
11.2.1.5.4.2. Market
Forecast, 2020 – 2028
11.2.1.5.5. Latin
America
11.2.1.5.5.1. Market
Estimation, 2015 – 2019
11.2.1.5.5.2. Market
Forecast, 2020 – 2028
11.2.2. Autoimmune
Diseases
11.2.2.1. Definition
11.2.2.2. Market
Estimation and Penetration, 2015 – 2019
11.2.2.3. Market
Forecast, 2020 – 2028
11.2.2.4. Compound
Annual Growth Rate (CAGR)
11.2.2.5. Regional
Bifurcation
11.2.2.5.1. North
America
11.2.2.5.1.1. Market
Estimation, 2015 – 2019
11.2.2.5.1.2. Market
Forecast, 2020 – 2028
11.2.2.5.2. Europe
11.2.2.5.2.1. Market
Estimation, 2015 – 2019
11.2.2.5.2.2. Market
Forecast, 2020 – 2028
11.2.2.5.3. Asia
Pacific
11.2.2.5.3.1. Market
Estimation, 2015 – 2019
11.2.2.5.3.2. Market
Forecast, 2020 – 2028
11.2.2.5.4. Middle
East and Africa
11.2.2.5.4.1. Market
Estimation, 2015 – 2019
11.2.2.5.4.2. Market
Forecast, 2020 – 2028
11.2.2.5.5. Latin
America
11.2.2.5.5.1. Market
Estimation, 2015 – 2019
11.2.2.5.5.2. Market
Forecast, 2020 – 2028
11.2.3. Cancer
Treatment (Definition, Market Estimation and Penetration, 2015 – 2019, Market
Estimation (2015 – 2019), Market Forecast (2020 – 2028), Compound Annual Growth
Rate (CAGR), Regional Bifurcation (North America, Europe, Asia Pacific, Middle
East and Africa, Latin America) and Information on Breast Cancer, Stomach
Cancer, Others)
11.2.3.1. Breast
Cancer
11.2.3.2. Stomach
Cancer
11.2.3.3. Others
11.2.4. Pregnancy
Testing
11.2.4.1. Definition
11.2.4.2. Market
Estimation and Penetration, 2015 – 2019
11.2.4.3. Market
Forecast, 2020 – 2028
11.2.4.4. Compound
Annual Growth Rate (CAGR)
11.2.4.5. Regional
Bifurcation
11.2.4.5.1. North
America
11.2.4.5.1.1. Market
Estimation, 2015 – 2019
11.2.4.5.1.2. Market
Forecast, 2020 – 2028
11.2.4.5.2. Europe
11.2.4.5.2.1. Market
Estimation, 2015 – 2019
11.2.4.5.2.2. Market
Forecast, 2020 – 2028
11.2.4.5.3. Asia
Pacific
11.2.4.5.3.1. Market
Estimation, 2015 – 2019
11.2.4.5.3.2. Market
Forecast, 2020 – 2028
11.2.4.5.4. Middle
East and Africa
11.2.4.5.4.1. Market
Estimation, 2015 – 2019
11.2.4.5.4.2. Market
Forecast, 2020 – 2028
11.2.4.5.5. Latin
America
11.2.4.5.5.1. Market
Estimation, 2015 – 2019
11.2.4.5.5.2. Market
Forecast, 2020 – 2028
11.2.5. Radioimmunodetection
(RID) of Cancer
11.2.5.1. Definition
11.2.5.2. Market
Estimation and Penetration, 2015 – 2019
11.2.5.3. Market
Forecast, 2020 – 2028
11.2.5.4. Compound
Annual Growth Rate (CAGR)
11.2.5.5. Regional
Bifurcation
11.2.5.5.1. North
America
11.2.5.5.1.1. Market
Estimation, 2015 – 2019
11.2.5.5.1.2. Market
Forecast, 2020 – 2028
11.2.5.5.2. Europe
11.2.5.5.2.1. Market
Estimation, 2015 – 2019
11.2.5.5.2.2. Market
Forecast, 2020 – 2028
11.2.5.5.3. Asia
Pacific
11.2.5.5.3.1. Market
Estimation, 2015 – 2019
11.2.5.5.3.2. Market
Forecast, 2020 – 2028
11.2.5.5.4. Middle
East and Africa
11.2.5.5.4.1. Market
Estimation, 2015 – 2019
11.2.5.5.4.2. Market
Forecast, 2020 – 2028
11.2.5.5.5. Latin
America
11.2.5.5.5.1. Market
Estimation, 2015 – 2019
11.2.5.5.5.2. Market
Forecast, 2020 – 2028
11.2.6. Radioimmunotheraphy
(RIT) of Cancer
11.2.6.1. Definition
11.2.6.2. Market
Estimation and Penetration, 2015 – 2019
11.2.6.3. Market
Forecast, 2020 – 2028
11.2.6.4. Compound
Annual Growth Rate (CAGR)
11.2.6.5. Regional
Bifurcation
11.2.6.5.1. North
America
11.2.6.5.1.1. Market
Estimation, 2015 – 2019
11.2.6.5.1.2. Market
Forecast, 2020 – 2028
11.2.6.5.2. Europe
11.2.6.5.2.1. Market
Estimation, 2015 – 2019
11.2.6.5.2.2. Market
Forecast, 2020 – 2028
11.2.6.5.3. Asia
Pacific
11.2.6.5.3.1. Market
Estimation, 2015 – 2019
11.2.6.5.3.2. Market
Forecast, 2020 – 2028
11.2.6.5.4. Middle
East and Africa
11.2.6.5.4.1. Market
Estimation, 2015 – 2019
11.2.6.5.4.2. Market
Forecast, 2020 – 2028
11.2.6.5.5. Latin
America
11.2.6.5.5.1. Market
Estimation, 2015 – 2019
11.2.6.5.5.2. Market
Forecast, 2020 – 2028
11.2.7. Viral
Disease Treatment
11.2.7.1. Definition
11.2.7.2. Market
Estimation and Penetration, 2015 – 2019
11.2.7.3. Market
Forecast, 2020 – 2028
11.2.7.4. Compound
Annual Growth Rate (CAGR)
11.2.7.5. Regional
Bifurcation
11.2.7.5.1. North
America
11.2.7.5.1.1. Market
Estimation, 2015 – 2019
11.2.7.5.1.2. Market
Forecast, 2020 – 2028
11.2.7.5.2. Europe
11.2.7.5.2.1. Market
Estimation, 2015 – 2019
11.2.7.5.2.2. Market
Forecast, 2020 – 2028
11.2.7.5.3. Asia
Pacific
11.2.7.5.3.1. Market
Estimation, 2015 – 2019
11.2.7.5.3.2. Market
Forecast, 2020 – 2028
11.2.7.5.4. Middle
East and Africa
11.2.7.5.4.1. Market
Estimation, 2015 – 2019
11.2.7.5.4.2. Market
Forecast, 2020 – 2028
11.2.7.5.5. Latin
America
11.2.7.5.5.1. Market
Estimation, 2015 – 2019
11.2.7.5.5.2. Market
Forecast, 2020 – 2028
11.2.8. Identifying
Pathogens
11.2.8.1. Definition
11.2.8.2. Market
Estimation and Penetration, 2015 – 2019
11.2.8.3. Market
Forecast, 2020 – 2028
11.2.8.4. Compound
Annual Growth Rate (CAGR)
11.2.8.5. Regional
Bifurcation
11.2.8.5.1. North
America
11.2.8.5.1.1. Market
Estimation, 2015 – 2019
11.2.8.5.1.2. Market
Forecast, 2020 – 2028
11.2.8.5.2. Europe
11.2.8.5.2.1. Market
Estimation, 2015 – 2019
11.2.8.5.2.2. Market
Forecast, 2020 – 2028
11.2.8.5.3. Asia
Pacific
11.2.8.5.3.1. Market
Estimation, 2015 – 2019
11.2.8.5.3.2. Market
Forecast, 2020 – 2028
11.2.8.5.4. Middle
East and Africa
11.2.8.5.4.1. Market
Estimation, 2015 – 2019
11.2.8.5.4.2. Market
Forecast, 2020 – 2028
11.2.8.5.5. Latin
America
11.2.8.5.5.1. Market
Estimation, 2015 – 2019
11.2.8.5.5.2. Market
Forecast, 2020 – 2028
11.2.9. Alzheimer’s
disease
11.2.9.1. Definition
11.2.9.2. Market
Estimation and Penetration, 2015 – 2019
11.2.9.3. Market
Forecast, 2020 – 2028
11.2.9.4. Compound
Annual Growth Rate (CAGR)
11.2.9.5. Regional
Bifurcation
11.2.9.5.1. North
America
11.2.9.5.1.1. Market
Estimation, 2015 – 2019
11.2.9.5.1.2. Market
Forecast, 2020 – 2028
11.2.9.5.2. Europe
11.2.9.5.2.1. Market
Estimation, 2015 – 2019
11.2.9.5.2.2. Market
Forecast, 2020 – 2028
11.2.9.5.3. Asia
Pacific
11.2.9.5.3.1. Market
Estimation, 2015 – 2019
11.2.9.5.3.2. Market
Forecast, 2020 – 2028
11.2.9.5.4. Middle
East and Africa
11.2.9.5.4.1. Market
Estimation, 2015 – 2019
11.2.9.5.4.2. Market
Forecast, 2020 – 2028
11.2.9.5.5. Latin
America
11.2.9.5.5.1. Market
Estimation, 2015 – 2019
11.2.9.5.5.2. Market
Forecast, 2020 – 2028
11.2.10. Chronic
lymphocytic leukemia and non-Hodgkin’s lymphoma
11.2.10.1. Definition
11.2.10.2. Market
Estimation and Penetration, 2015 – 2019
11.2.10.3. Market
Forecast, 2020 – 2028
11.2.10.4. Compound
Annual Growth Rate (CAGR)
11.2.10.5. Regional
Bifurcation
11.2.10.5.1. North
America
11.2.10.5.1.1. Market
Estimation, 2015 – 2019
11.2.10.5.1.2. Market
Forecast, 2020 – 2028
11.2.10.5.2. Europe
11.2.10.5.2.1. Market
Estimation, 2015 – 2019
11.2.10.5.2.2. Market
Forecast, 2020 – 2028
11.2.10.5.3. Asia
Pacific
11.2.10.5.3.1. Market
Estimation, 2015 – 2019
11.2.10.5.3.2. Market
Forecast, 2020 – 2028
11.2.10.5.4. Middle
East and Africa
11.2.10.5.4.1. Market
Estimation, 2015 – 2019
11.2.10.5.4.2. Market
Forecast, 2020 – 2028
11.2.10.5.5. Latin
America
11.2.10.5.5.1. Market
Estimation, 2015 – 2019
11.2.10.5.5.2. Market
Forecast, 2020 – 2028
11.2.11. Rhesus
disease Immunisation
11.2.11.1. Definition
11.2.11.2. Market
Estimation and Penetration, 2015 – 2019
11.2.11.3. Market
Forecast, 2020 – 2028
11.2.11.4. Compound
Annual Growth Rate (CAGR)
11.2.11.5. Regional
Bifurcation
11.2.11.5.1. North
America
11.2.11.5.1.1. Market
Estimation, 2015 – 2019
11.2.11.5.1.2. Market
Forecast, 2020 – 2028
11.2.11.5.2. Europe
11.2.11.5.2.1. Market
Estimation, 2015 – 2019
11.2.11.5.2.2. Market
Forecast, 2020 – 2028
11.2.11.5.3. Asia
Pacific
11.2.11.5.3.1. Market
Estimation, 2015 – 2019
11.2.11.5.3.2. Market
Forecast, 2020 – 2028
11.2.11.5.4. Middle
East and Africa
11.2.11.5.4.1. Market
Estimation, 2015 – 2019
11.2.11.5.4.2. Market
Forecast, 2020 – 2028
11.2.11.5.5. Latin
America
11.2.11.5.5.1. Market
Estimation, 2015 – 2019
11.2.11.5.5.2. Market
Forecast, 2020 – 2028
11.2.12. Systemic
Lupus Erythematosus
11.2.12.1. Definition
11.2.12.2. Market
Estimation and Penetration, 2015 – 2019
11.2.12.3. Market
Forecast, 2020 – 2028
11.2.12.4. Compound
Annual Growth Rate (CAGR)
11.2.12.5. Regional
Bifurcation
11.2.12.5.1. North
America
11.2.12.5.1.1. Market
Estimation, 2015 – 2019
11.2.12.5.1.2. Market
Forecast, 2020 – 2028
11.2.12.5.2. Europe
11.2.12.5.2.1. Market
Estimation, 2015 – 2019
11.2.12.5.2.2. Market
Forecast, 2020 – 2028
11.2.12.5.3. Asia
Pacific
11.2.12.5.3.1. Market
Estimation, 2015 – 2019
11.2.12.5.3.2. Market
Forecast, 2020 – 2028
11.2.12.5.4. Middle
East and Africa
11.2.12.5.4.1. Market
Estimation, 2015 – 2019
11.2.12.5.4.2. Market
Forecast, 2020 – 2028
11.2.12.5.5. Latin
America
11.2.12.5.5.1. Market
Estimation, 2015 – 2019
11.2.12.5.5.2. Market
Forecast, 2020 – 2028
11.2.13. Crohn's
Disease
11.2.13.1. Definition
11.2.13.2. Market
Estimation and Penetration, 2015 – 2019
11.2.13.3. Market
Forecast, 2020 – 2028
11.2.13.4. Compound
Annual Growth Rate (CAGR)
11.2.13.5. Regional
Bifurcation
11.2.13.5.1. North
America
11.2.13.5.1.1. Market
Estimation, 2015 – 2019
11.2.13.5.1.2. Market
Forecast, 2020 – 2028
11.2.13.5.2. Europe
11.2.13.5.2.1. Market
Estimation, 2015 – 2019
11.2.13.5.2.2. Market
Forecast, 2020 – 2028
11.2.13.5.3. Asia
Pacific
11.2.13.5.3.1. Market
Estimation, 2015 – 2019
11.2.13.5.3.2. Market
Forecast, 2020 – 2028
11.2.13.5.4. Middle
East and Africa
11.2.13.5.4.1. Market
Estimation, 2015 – 2019
11.2.13.5.4.2. Market
Forecast, 2020 – 2028
11.2.13.5.5. Latin
America
11.2.13.5.5.1. Market
Estimation, 2015 – 2019
11.2.13.5.5.2. Market
Forecast, 2020 – 2028
11.2.14. Ulcerative
Colitis
11.2.14.1. Definition
11.2.14.2. Market
Estimation and Penetration, 2015 – 2019
11.2.14.3. Market
Forecast, 2020 – 2028
11.2.14.4. Compound
Annual Growth Rate (CAGR)
11.2.14.5. Regional
Bifurcation
11.2.14.5.1. North
America
11.2.14.5.1.1. Market
Estimation, 2015 – 2019
11.2.14.5.1.2. Market
Forecast, 2020 – 2028
11.2.14.5.2. Europe
11.2.14.5.2.1. Market
Estimation, 2015 – 2019
11.2.14.5.2.2. Market
Forecast, 2020 – 2028
11.2.14.5.3. Asia
Pacific
11.2.14.5.3.1. Market
Estimation, 2015 – 2019
11.2.14.5.3.2. Market
Forecast, 2020 – 2028
11.2.14.5.4. Middle
East and Africa
11.2.14.5.4.1. Market
Estimation, 2015 – 2019
11.2.14.5.4.2. Market
Forecast, 2020 – 2028
11.2.14.5.5. Latin
America
11.2.14.5.5.1. Market
Estimation, 2015 – 2019
11.2.14.5.5.2. Market
Forecast, 2020 – 2028
11.2.15. Psoriasis
and Rheumatoid Arthritis
11.2.15.1. Definition
11.2.15.2. Market
Estimation and Penetration, 2015 – 2019
11.2.15.3. Market
Forecast, 2020 – 2028
11.2.15.4. Compound
Annual Growth Rate (CAGR)
11.2.15.5. Regional
Bifurcation
11.2.15.5.1. North
America
11.2.15.5.1.1. Market
Estimation, 2015 – 2019
11.2.15.5.1.2. Market
Forecast, 2020 – 2028
11.2.15.5.2. Europe
11.2.15.5.2.1. Market
Estimation, 2015 – 2019
11.2.15.5.2.2. Market
Forecast, 2020 – 2028
11.2.15.5.3. Asia
Pacific
11.2.15.5.3.1. Market
Estimation, 2015 – 2019
11.2.15.5.3.2. Market
Forecast, 2020 – 2028
11.2.15.5.4. Middle
East and Africa
11.2.15.5.4.1. Market
Estimation, 2015 – 2019
11.2.15.5.4.2. Market
Forecast, 2020 – 2028
11.2.15.5.5. Latin
America
11.2.15.5.5.1. Market
Estimation, 2015 – 2019
11.2.15.5.5.2. Market
Forecast, 2020 – 2028
11.2.16. Cardiovascular
Disease
11.2.16.1. Definition
11.2.16.2. Market
Estimation and Penetration, 2015 – 2019
11.2.16.3. Market
Forecast, 2020 – 2028
11.2.16.4. Compound
Annual Growth Rate (CAGR)
11.2.16.5. Regional
Bifurcation
11.2.16.5.1. North
America
11.2.16.5.1.1. Market
Estimation, 2015 – 2019
11.2.16.5.1.2. Market
Forecast, 2020 – 2028
11.2.16.5.2. Europe
11.2.16.5.2.1. Market
Estimation, 2015 – 2019
11.2.16.5.2.2. Market
Forecast, 2020 – 2028
11.2.16.5.3. Asia
Pacific
11.2.16.5.3.1. Market
Estimation, 2015 – 2019
11.2.16.5.3.2. Market
Forecast, 2020 – 2028
11.2.16.5.4. Middle
East and Africa
11.2.16.5.4.1. Market
Estimation, 2015 – 2019
11.2.16.5.4.2. Market
Forecast, 2020 – 2028
11.2.16.5.5. Latin
America
11.2.16.5.5.1. Market
Estimation, 2015 – 2019
11.2.16.5.5.2. Market
Forecast, 2020 – 2028
11.2.17. Others
11.2.17.1. Definition
11.2.17.2. Market
Estimation and Penetration, 2015 – 2019
11.2.17.3. Market
Forecast, 2020 – 2028
11.2.17.4. Compound
Annual Growth Rate (CAGR)
11.2.17.5. Regional
Bifurcation
11.2.17.5.1. North
America
11.2.17.5.1.1. Market
Estimation, 2015 – 2019
11.2.17.5.1.2. Market
Forecast, 2020 – 2028
11.2.17.5.2. Europe
11.2.17.5.2.1. Market
Estimation, 2015 – 2019
11.2.17.5.2.2. Market
Forecast, 2020 – 2028
11.2.17.5.3. Asia
Pacific
11.2.17.5.3.1. Market
Estimation, 2015 – 2019
11.2.17.5.3.2. Market
Forecast, 2020 – 2028
11.2.17.5.4. Middle
East and Africa
11.2.17.5.4.1. Market
Estimation, 2015 – 2019
11.2.17.5.4.2. Market
Forecast, 2020 – 2028
11.2.17.5.5. Latin
America
11.2.17.5.5.1. Market
Estimation, 2015 – 2019
11.2.17.5.5.2. Market
Forecast, 2020 – 2028
11.3. Key
Segment for Channeling Investments
11.3.1. By
Application
12. Global
Monoclonal Antibodies Market Analysis and Forecasts, 2020 – 2028
12.1. Overview
12.2. Global
Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By End Use
12.2.1. Hospitals
12.2.1.1. Definition
12.2.1.2. Market
Estimation and Penetration, 2015 – 2019
12.2.1.3. Market
Forecast, 2020 – 2028
12.2.1.4. Compound
Annual Growth Rate (CAGR)
12.2.1.5. Regional
Bifurcation
12.2.1.5.1. North
America
12.2.1.5.1.1. Market
Estimation, 2015 – 2019
12.2.1.5.1.2. Market
Forecast, 2020 – 2028
12.2.1.5.2. Europe
12.2.1.5.2.1. Market
Estimation, 2015 – 2019
12.2.1.5.2.2. Market
Forecast, 2020 – 2028
12.2.1.5.3. Asia
Pacific
12.2.1.5.3.1. Market
Estimation, 2015 – 2019
12.2.1.5.3.2. Market
Forecast, 2020 – 2028
12.2.1.5.4. Middle
East and Africa
12.2.1.5.4.1. Market
Estimation, 2015 – 2019
12.2.1.5.4.2. Market
Forecast, 2020 – 2028
12.2.1.5.5. Latin
America
12.2.1.5.5.1. Market
Estimation, 2015 – 2019
12.2.1.5.5.2. Market
Forecast, 2020 – 2028
12.2.2. Clinics
12.2.2.1. Definition
12.2.2.2. Market
Estimation and Penetration, 2015 – 2019
12.2.2.3. Market
Forecast, 2020 – 2028
12.2.2.4. Compound
Annual Growth Rate (CAGR)
12.2.2.5. Regional
Bifurcation
12.2.2.5.1. North
America
12.2.2.5.1.1. Market
Estimation, 2015 – 2019
12.2.2.5.1.2. Market
Forecast, 2020 – 2028
12.2.2.5.2. Europe
12.2.2.5.2.1. Market
Estimation, 2015 – 2019
12.2.2.5.2.2. Market
Forecast, 2020 – 2028
12.2.2.5.3. Asia
Pacific
12.2.2.5.3.1. Market
Estimation, 2015 – 2019
12.2.2.5.3.2. Market
Forecast, 2020 – 2028
12.2.2.5.4. Middle
East and Africa
12.2.2.5.4.1. Market
Estimation, 2015 – 2019
12.2.2.5.4.2. Market
Forecast, 2020 – 2028
12.2.2.5.5. Latin
America
12.2.2.5.5.1. Market
Estimation, 2015 – 2019
12.2.2.5.5.2. Market
Forecast, 2020 – 2028
12.2.3. Research
Institutes
12.2.3.1. Definition
12.2.3.2. Market
Estimation and Penetration, 2015 – 2019
12.2.3.3. Market
Forecast, 2020 – 2028
12.2.3.4. Compound
Annual Growth Rate (CAGR)
12.2.3.5. Regional
Bifurcation
12.2.3.5.1. North
America
12.2.3.5.1.1. Market
Estimation, 2015 – 2019
12.2.3.5.1.2. Market
Forecast, 2020 – 2028
12.2.3.5.2. Europe
12.2.3.5.2.1. Market
Estimation, 2015 – 2019
12.2.3.5.2.2. Market
Forecast, 2020 – 2028
12.2.3.5.3. Asia
Pacific
12.2.3.5.3.1. Market
Estimation, 2015 – 2019
12.2.3.5.3.2. Market
Forecast, 2020 – 2028
12.2.3.5.4. Middle
East and Africa
12.2.3.5.4.1. Market
Estimation, 2015 – 2019
12.2.3.5.4.2. Market
Forecast, 2020 – 2028
12.2.3.5.5. Latin
America
12.2.3.5.5.1. Market
Estimation, 2015 – 2019
12.2.3.5.5.2. Market
Forecast, 2020 – 2028
12.2.4. Others
12.2.4.1. Definition
12.2.4.2. Market
Estimation and Penetration, 2015 – 2019
12.2.4.3. Market
Forecast, 2020 – 2028
12.2.4.4. Compound
Annual Growth Rate (CAGR)
12.2.4.5. Regional
Bifurcation
12.2.4.5.1. North
America
12.2.4.5.1.1. Market
Estimation, 2015 – 2019
12.2.4.5.1.2. Market
Forecast, 2020 – 2028
12.2.4.5.2. Europe
12.2.4.5.2.1. Market
Estimation, 2015 – 2019
12.2.4.5.2.2. Market
Forecast, 2020 – 2028
12.2.4.5.3. Asia
Pacific
12.2.4.5.3.1. Market
Estimation, 2015 – 2019
12.2.4.5.3.2. Market
Forecast, 2020 – 2028
12.2.4.5.4. Middle
East and Africa
12.2.4.5.4.1. Market
Estimation, 2015 – 2019
12.2.4.5.4.2. Market
Forecast, 2020 – 2028
12.2.4.5.5. Latin
America
12.2.4.5.5.1. Market
Estimation, 2015 – 2019
12.2.4.5.5.2. Market
Forecast, 2020 – 2028
12.3. Key
Segment for Channeling Investments
12.3.1. By End
Use
13. North
America Monoclonal Antibodies Market Analysis and Forecasts, 2020 - 2028
13.1. Overview
13.1.1. North
America Monoclonal Antibodies Market Revenue (US$ Mn)
13.2. North
America Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Source
13.2.1. Murine
13.2.2. Chimeric
13.2.3. Humanized
13.2.4. Human
13.3. North
America Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Type
13.3.1. Naked
Monoclonal Antibodies
13.3.2. Conjugated
Monoclonal Antibodies
13.3.3. Bispecific
Monoclonal Antibodies
13.3.4. Others
13.4. North
America Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By
Clinical Trial Phases
13.4.1. Phase 0
13.4.2. Phase I
13.4.3. Phase
II
13.4.4. Phase
III
13.4.5. Phase
IV
13.5. North
America Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By
Application
13.5.1. Diagnostic
Testing
13.5.2. Autoimmune
Diseases
13.5.3. Cancer
Treatment
13.5.3.1. Breast
Cancer
13.5.3.2. Stomach
Cancer
13.5.3.3. Others
13.5.4. Pregnancy
Testing
13.5.5. Radioimmunodetection
(RID) of Cancer
13.5.6. Radioimmunotheraphy
(RIT) of Cancer
13.5.7. Viral
Disease Treatment
13.5.8. Identifying
Pathogens
13.5.9. Alzheimer’s
disease
13.5.10. Chronic
lymphocytic leukemia and non-Hodgkin’s lymphoma
13.5.11. Rhesus
disease Immunisation
13.5.12. Systemic
Lupus Erythematosus
13.5.13. Crohn's
Disease
13.5.14. Ulcerative
Colitis
13.5.15. Psoriasis
and Rheumatoid Arthritis
13.5.16. Cardiovascular
Disease
13.5.17. Others
13.6. North
America Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By End Use
13.6.1. Hospitals
13.6.2. Clinics
13.6.3. Research
Institutes
13.6.4. Others
13.7. North
America Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Country
13.7.1. U.S
13.7.1.1. U.S
Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Source
13.7.1.1.1. Murine
13.7.1.1.2. Chimeric
13.7.1.1.3. Humanized
13.7.1.1.4. Human
13.7.1.2. U.S
Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Type
13.7.1.2.1. Naked
Monoclonal Antibodies
13.7.1.2.2. Conjugated
Monoclonal Antibodies
13.7.1.2.3. Bispecific
Monoclonal Antibodies
13.7.1.2.4. Others
13.7.1.3. U.S
Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Clinical Trial
Phases
13.7.1.3.1. Phase
0
13.7.1.3.2. Phase
I
13.7.1.3.3. Phase
II
13.7.1.3.4. Phase
III
13.7.1.3.5. Phase
IV
13.7.1.4. U.S
Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Application
13.7.1.4.1. Diagnostic
Testing
13.7.1.4.2. Autoimmune
Diseases
13.7.1.4.3. Cancer
Treatment
13.7.1.4.3.1. Breast
Cancer
13.7.1.4.3.2. Stomach
Cancer
13.7.1.4.3.3. Others
13.7.1.4.4. Pregnancy
Testing
13.7.1.4.5. Radioimmunodetection
(RID) of Cancer
13.7.1.4.6. Radioimmunotheraphy
(RIT) of Cancer
13.7.1.4.7. Viral
Disease Treatment
13.7.1.4.8. Identifying
Pathogens
13.7.1.4.9. Alzheimer’s
disease
13.7.1.4.10. Chronic
lymphocytic leukemia and non-Hodgkin’s lymphoma
13.7.1.4.11. Rhesus
disease Immunisation
13.7.1.4.12. Systemic
Lupus Erythematosus
13.7.1.4.13. Crohn's
Disease
13.7.1.4.14. Ulcerative
Colitis
13.7.1.4.15. Psoriasis
and Rheumatoid Arthritis
13.7.1.4.16. Cardiovascular
Disease
13.7.1.4.17. Others
13.7.1.5. U.S
Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By End Use
13.7.1.5.1. Hospitals
13.7.1.5.2. Clinics
13.7.1.5.3. Research
Institutes
13.7.1.5.4. Others
13.7.2. Canada
13.7.2.1. Canada
Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Source
13.7.2.1.1. Murine
13.7.2.1.2. Chimeric
13.7.2.1.3. Humanized
13.7.2.1.4. Human
13.7.2.2. Canada
Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Type
13.7.2.2.1. Naked
Monoclonal Antibodies
13.7.2.2.2. Conjugated
Monoclonal Antibodies
13.7.2.2.3. Bispecific
Monoclonal Antibodies
13.7.2.2.4. Others
13.7.2.3. Canada
Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Clinical Trial
Phases
13.7.2.3.1. Phase
0
13.7.2.3.2. Phase
I
13.7.2.3.3. Phase
II
13.7.2.3.4. Phase
III
13.7.2.3.5. Phase
IV
13.7.2.4. Canada
Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Application
13.7.2.4.1. Diagnostic
Testing
13.7.2.4.2. Autoimmune
Diseases
13.7.2.4.3. Cancer
Treatment
13.7.2.4.3.1. Breast
Cancer
13.7.2.4.3.2. Stomach
Cancer
13.7.2.4.3.3. Others
13.7.2.4.4. Pregnancy
Testing
13.7.2.4.5. Radioimmunodetection
(RID) of Cancer
13.7.2.4.6. Radioimmunotheraphy
(RIT) of Cancer
13.7.2.4.7. Viral
Disease Treatment
13.7.2.4.8. Identifying
Pathogens
13.7.2.4.9. Alzheimer’s
disease
13.7.2.4.10. Chronic
lymphocytic leukemia and non-Hodgkin’s lymphoma
13.7.2.4.11. Rhesus
disease Immunisation
13.7.2.4.12. Systemic
Lupus Erythematosus
13.7.2.4.13. Crohn's
Disease
13.7.2.4.14. Ulcerative
Colitis
13.7.2.4.15. Psoriasis
and Rheumatoid Arthritis
13.7.2.4.16. Cardiovascular
Disease
13.7.2.4.17. Others
13.7.2.5. Canada
Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By End Use
13.7.2.5.1. Hospitals
13.7.2.5.2. Clinics
13.7.2.5.3. Research
Institutes
13.7.2.5.4. Others
13.7.3. Mexico
13.7.3.1. Mexico
Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Source
13.7.3.1.1. Murine
13.7.3.1.2. Chimeric
13.7.3.1.3. Humanized
13.7.3.1.4. Human
13.7.3.2. Mexico
Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Type
13.7.3.2.1. Naked
Monoclonal Antibodies
13.7.3.2.2. Conjugated
Monoclonal Antibodies
13.7.3.2.3. Bispecific
Monoclonal Antibodies
13.7.3.2.4. Others
13.7.3.3. Mexico
Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Clinical Trial
Phases
13.7.3.3.1. Phase
0
13.7.3.3.2. Phase
I
13.7.3.3.3. Phase
II
13.7.3.3.4. Phase
III
13.7.3.3.5. Phase
IV
13.7.3.4. Mexico
Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Application
13.7.3.4.1. Diagnostic
Testing
13.7.3.4.2. Autoimmune
Diseases
13.7.3.4.3. Cancer
Treatment
13.7.3.4.3.1. Breast
Cancer
13.7.3.4.3.2. Stomach
Cancer
13.7.3.4.3.3. Others
13.7.3.4.4. Pregnancy
Testing
13.7.3.4.5. Radioimmunodetection
(RID) of Cancer
13.7.3.4.6. Radioimmunotheraphy
(RIT) of Cancer
13.7.3.4.7. Viral
Disease Treatment
13.7.3.4.8. Identifying
Pathogens
13.7.3.4.9. Alzheimer’s
disease
13.7.3.4.10. Chronic
lymphocytic leukemia and non-Hodgkin’s lymphoma
13.7.3.4.11. Rhesus
disease Immunisation
13.7.3.4.12. Systemic
Lupus Erythematosus
13.7.3.4.13. Crohn's
Disease
13.7.3.4.14. Ulcerative
Colitis
13.7.3.4.15. Psoriasis
and Rheumatoid Arthritis
13.7.3.4.16. Cardiovascular
Disease
13.7.3.4.17. Others
13.7.3.5. Mexico
Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By End Use
13.7.3.5.1. Hospitals
13.7.3.5.2. Clinics
13.7.3.5.3. Research
Institutes
13.7.3.5.4. Others
13.7.4. Rest of
North America
13.7.4.1. Rest
of North America Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts,
By Source
13.7.4.1.1. Murine
13.7.4.1.2. Chimeric
13.7.4.1.3. Humanized
13.7.4.1.4. Human
13.7.4.2. Rest
of North America Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts,
By Type
13.7.4.2.1. Naked
Monoclonal Antibodies
13.7.4.2.2. Conjugated
Monoclonal Antibodies
13.7.4.2.3. Bispecific
Monoclonal Antibodies
13.7.4.2.4. Others
13.7.4.3. Rest
of North America Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts,
By Clinical Trial Phases
13.7.4.3.1. Phase
0
13.7.4.3.2. Phase
I
13.7.4.3.3. Phase
II
13.7.4.3.4. Phase
III
13.7.4.3.5. Phase
IV
13.7.4.4. Rest
of North America Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts,
By Application
13.7.4.4.1. Diagnostic
Testing
13.7.4.4.2. Autoimmune
Diseases
13.7.4.4.3. Cancer
Treatment
13.7.4.4.3.1. Breast
Cancer
13.7.4.4.3.2. Stomach
Cancer
13.7.4.4.3.3. Others
13.7.4.4.4. Pregnancy
Testing
13.7.4.4.5. Radioimmunodetection
(RID) of Cancer
13.7.4.4.6. Radioimmunotheraphy
(RIT) of Cancer
13.7.4.4.7. Viral
Disease Treatment
13.7.4.4.8. Identifying
Pathogens
13.7.4.4.9. Alzheimer’s
disease
13.7.4.4.10. Chronic
lymphocytic leukemia and non-Hodgkin’s lymphoma
13.7.4.4.11. Rhesus
disease Immunisation
13.7.4.4.12. Systemic
Lupus Erythematosus
13.7.4.4.13. Crohn's
Disease
13.7.4.4.14. Ulcerative
Colitis
13.7.4.4.15. Psoriasis
and Rheumatoid Arthritis
13.7.4.4.16. Cardiovascular
Disease
13.7.4.4.17. Others
13.7.4.5. Rest
of North America Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts,
By End Use
13.7.4.5.1. Hospitals
13.7.4.5.2. Clinics
13.7.4.5.3. Research
Institutes
13.7.4.5.4. Others
13.8. Key
Segment for Channeling Investments
13.8.1. By
Country
13.8.2. By Source
13.8.3. By Type
13.8.4. By
Clinical Trial Phases
13.8.5. By
Application
13.8.6. By End
Use
14. Europe
Monoclonal Antibodies Market Analysis and Forecasts, 2020 - 2028
14.1. Overview
14.1.1. Europe
Monoclonal Antibodies Market Revenue (US$ Mn)
14.2. Europe
Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Source
14.2.1. Murine
14.2.2. Chimeric
14.2.3. Humanized
14.2.4. Human
14.3. Europe
Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Type
14.3.1. Naked
Monoclonal Antibodies
14.3.2. Conjugated
Monoclonal Antibodies
14.3.3. Bispecific
Monoclonal Antibodies
14.3.4. Others
14.4. Europe
Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Clinical Trial
Phases
14.4.1. Phase 0
14.4.2. Phase I
14.4.3. Phase
II
14.4.4. Phase
III
14.4.5. Phase
IV
14.5. Europe
Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Application
14.5.1. Diagnostic
Testing
14.5.2. Autoimmune
Diseases
14.5.3. Cancer
Treatment
14.5.3.1. Breast
Cancer
14.5.3.2. Stomach
Cancer
14.5.3.3. Others
14.5.4. Pregnancy
Testing
14.5.5. Radioimmunodetection
(RID) of Cancer
14.5.6. Radioimmunotheraphy
(RIT) of Cancer
14.5.7. Viral
Disease Treatment
14.5.8. Identifying
Pathogens
14.5.9. Alzheimer’s
disease
14.5.10. Chronic
lymphocytic leukemia and non-Hodgkin’s lymphoma
14.5.11. Rhesus
disease Immunisation
14.5.12. Systemic
Lupus Erythematosus
14.5.13. Crohn's
Disease
14.5.14. Ulcerative
Colitis
14.5.15. Psoriasis
and Rheumatoid Arthritis
14.5.16. Cardiovascular
Disease
14.5.17. Others
14.6. Europe
Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By End Use
14.6.1. Hospitals
14.6.2. Clinics
14.6.3. Research
Institutes
14.6.4. Others
14.7. Europe
Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Country
14.7.1. France
14.7.1.1. France
Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Source
14.7.1.1.1. Murine
14.7.1.1.2. Chimeric
14.7.1.1.3. Humanized
14.7.1.1.4. Human
14.7.1.2. France
Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Type
14.7.1.2.1. Naked
Monoclonal Antibodies
14.7.1.2.2. Conjugated
Monoclonal Antibodies
14.7.1.2.3. Bispecific
Monoclonal Antibodies
14.7.1.2.4. Others
14.7.1.3. France
Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Clinical Trial
Phases
14.7.1.3.1. Phase
0
14.7.1.3.2. Phase
I
14.7.1.3.3. Phase
II
14.7.1.3.4. Phase
III
14.7.1.3.5. Phase
IV
14.7.1.4. France
Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Application
14.7.1.4.1. Diagnostic
Testing
14.7.1.4.2. Autoimmune
Diseases
14.7.1.4.3. Cancer
Treatment
14.7.1.4.3.1. Breast
Cancer
14.7.1.4.3.2. Stomach
Cancer
14.7.1.4.3.3. Others
14.7.1.4.4. Pregnancy
Testing
14.7.1.4.5. Radioimmunodetection
(RID) of Cancer
14.7.1.4.6. Radioimmunotheraphy
(RIT) of Cancer
14.7.1.4.7. Viral
Disease Treatment
14.7.1.4.8. Identifying
Pathogens
14.7.1.4.9. Alzheimer’s
disease
14.7.1.4.10. Chronic
lymphocytic leukemia and non-Hodgkin’s lymphoma
14.7.1.4.11. Rhesus
disease Immunisation
14.7.1.4.12. Systemic
Lupus Erythematosus
14.7.1.4.13. Crohn's
Disease
14.7.1.4.14. Ulcerative
Colitis
14.7.1.4.15. Psoriasis
and Rheumatoid Arthritis
14.7.1.4.16. Cardiovascular
Disease
14.7.1.4.17. Others
14.7.1.5. France
Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By End Use
14.7.1.5.1. Hospitals
14.7.1.5.2. Clinics
14.7.1.5.3. Research
Institutes
14.7.1.5.4. Others
14.7.2. The UK
14.7.2.1. The
UK Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Source
14.7.2.1.1. Murine
14.7.2.1.2. Chimeric
14.7.2.1.3. Humanized
14.7.2.1.4. Human
14.7.2.2. The
UK Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Type
14.7.2.2.1. Naked
Monoclonal Antibodies
14.7.2.2.2. Conjugated
Monoclonal Antibodies
14.7.2.2.3. Bispecific
Monoclonal Antibodies
14.7.2.2.4. Others
14.7.2.3. The
UK Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Clinical
Trial Phases
14.7.2.3.1. Phase
0
14.7.2.3.2. Phase
I
14.7.2.3.3. Phase
II
14.7.2.3.4. Phase
III
14.7.2.3.5. Phase
IV
14.7.2.4. The
UK Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Application
14.7.2.4.1. Diagnostic
Testing
14.7.2.4.2. Autoimmune
Diseases
14.7.2.4.3. Cancer
Treatment
14.7.2.4.3.1. Breast
Cancer
14.7.2.4.3.2. Stomach
Cancer
14.7.2.4.3.3. Others
14.7.2.4.4. Pregnancy
Testing
14.7.2.4.5. Radioimmunodetection
(RID) of Cancer
14.7.2.4.6. Radioimmunotheraphy
(RIT) of Cancer
14.7.2.4.7. Viral
Disease Treatment
14.7.2.4.8. Identifying
Pathogens
14.7.2.4.9. Alzheimer’s
disease
14.7.2.4.10. Chronic
lymphocytic leukemia and non-Hodgkin’s lymphoma
14.7.2.4.11. Rhesus
disease Immunisation
14.7.2.4.12. Systemic
Lupus Erythematosus
14.7.2.4.13. Crohn's
Disease
14.7.2.4.14. Ulcerative
Colitis
14.7.2.4.15. Psoriasis
and Rheumatoid Arthritis
14.7.2.4.16. Cardiovascular
Disease
14.7.2.4.17. Others
14.7.2.5. The
UK Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By End Use
14.7.2.5.1. Hospitals
14.7.2.5.2. Clinics
14.7.2.5.3. Research
Institutes
14.7.2.5.4. Others
14.7.3. Spain
14.7.3.1. Spain
Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Source
14.7.3.1.1. Murine
14.7.3.1.2. Chimeric
14.7.3.1.3. Humanized
14.7.3.1.4. Human
14.7.3.2. Spain
Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Type
14.7.3.2.1. Naked
Monoclonal Antibodies
14.7.3.2.2. Conjugated
Monoclonal Antibodies
14.7.3.2.3. Bispecific
Monoclonal Antibodies
14.7.3.2.4. Others
14.7.3.3. Spain
Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Clinical Trial
Phases
14.7.3.3.1. Phase
0
14.7.3.3.2. Phase
I
14.7.3.3.3. Phase
II
14.7.3.3.4. Phase
III
14.7.3.3.5. Phase
IV
14.7.3.4. Spain
Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Application
14.7.3.4.1. Diagnostic
Testing
14.7.3.4.2. Autoimmune
Diseases
14.7.3.4.3. Cancer
Treatment
14.7.3.4.3.1. Breast
Cancer
14.7.3.4.3.2. Stomach
Cancer
14.7.3.4.3.3. Others
14.7.3.4.4. Pregnancy
Testing
14.7.3.4.5. Radioimmunodetection
(RID) of Cancer
14.7.3.4.6. Radioimmunotheraphy
(RIT) of Cancer
14.7.3.4.7. Viral
Disease Treatment
14.7.3.4.8. Identifying
Pathogens
14.7.3.4.9. Alzheimer’s
disease
14.7.3.4.10. Chronic
lymphocytic leukemia and non-Hodgkin’s lymphoma
14.7.3.4.11. Rhesus
disease Immunisation
14.7.3.4.12. Systemic
Lupus Erythematosus
14.7.3.4.13. Crohn's
Disease
14.7.3.4.14. Ulcerative
Colitis
14.7.3.4.15. Psoriasis
and Rheumatoid Arthritis
14.7.3.4.16. Cardiovascular
Disease
14.7.3.4.17. Others
14.7.3.5. Spain
Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By End Use
14.7.3.5.1. Hospitals
14.7.3.5.2. Clinics
14.7.3.5.3. Research
Institutes
14.7.3.5.4. Others
14.7.4. Germany
14.7.4.1. Germany
Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Source
14.7.4.1.1. Murine
14.7.4.1.2. Chimeric
14.7.4.1.3. Humanized
14.7.4.1.4. Human
14.7.4.2. Germany
Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Type
14.7.4.2.1. Naked
Monoclonal Antibodies
14.7.4.2.2. Conjugated
Monoclonal Antibodies
14.7.4.2.3. Bispecific
Monoclonal Antibodies
14.7.4.2.4. Others
14.7.4.3. Germany
Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Clinical Trial
Phases
14.7.4.3.1. Phase
0
14.7.4.3.2. Phase
I
14.7.4.3.3. Phase
II
14.7.4.3.4. Phase
III
14.7.4.3.5. Phase
IV
14.7.4.4. Germany
Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Application
14.7.4.4.1. Diagnostic
Testing
14.7.4.4.2. Autoimmune
Diseases
14.7.4.4.3. Cancer
Treatment
14.7.4.4.3.1. Breast
Cancer
14.7.4.4.3.2. Stomach
Cancer
14.7.4.4.3.3. Others
14.7.4.4.4. Pregnancy
Testing
14.7.4.4.5. Radioimmunodetection
(RID) of Cancer
14.7.4.4.6. Radioimmunotheraphy
(RIT) of Cancer
14.7.4.4.7. Viral
Disease Treatment
14.7.4.4.8. Identifying
Pathogens
14.7.4.4.9. Alzheimer’s
disease
14.7.4.4.10. Chronic
lymphocytic leukemia and non-Hodgkin’s lymphoma
14.7.4.4.11. Rhesus
disease Immunisation
14.7.4.4.12. Systemic
Lupus Erythematosus
14.7.4.4.13. Crohn's
Disease
14.7.4.4.14. Ulcerative
Colitis
14.7.4.4.15. Psoriasis
and Rheumatoid Arthritis
14.7.4.4.16. Cardiovascular
Disease
14.7.4.4.17. Others
14.7.4.5. Germany
Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By End Use
14.7.4.5.1. Hospitals
14.7.4.5.2. Clinics
14.7.4.5.3. Research
Institutes
14.7.4.5.4. Others
14.7.5. Italy
14.7.5.1. Italy
Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Source
14.7.5.1.1. Murine
14.7.5.1.2. Chimeric
14.7.5.1.3. Humanized
14.7.5.1.4. Human
14.7.5.2. Italy
Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Type
14.7.5.2.1. Naked
Monoclonal Antibodies
14.7.5.2.2. Conjugated
Monoclonal Antibodies
14.7.5.2.3. Bispecific
Monoclonal Antibodies
14.7.5.2.4. Others
14.7.5.3. Italy
Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Clinical Trial
Phases
14.7.5.3.1. Phase
0
14.7.5.3.2. Phase
I
14.7.5.3.3. Phase
II
14.7.5.3.4. Phase
III
14.7.5.3.5. Phase
IV
14.7.5.4. Italy
Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Application
14.7.5.4.1. Diagnostic
Testing
14.7.5.4.2. Autoimmune
Diseases
14.7.5.4.3. Cancer
Treatment
14.7.5.4.3.1. Breast
Cancer
14.7.5.4.3.2. Stomach
Cancer
14.7.5.4.3.3. Others
14.7.5.4.4. Pregnancy
Testing
14.7.5.4.5. Radioimmunodetection
(RID) of Cancer
14.7.5.4.6. Radioimmunotheraphy
(RIT) of Cancer
14.7.5.4.7. Viral
Disease Treatment
14.7.5.4.8. Identifying
Pathogens
14.7.5.4.9. Alzheimer’s
disease
14.7.5.4.10. Chronic
lymphocytic leukemia and non-Hodgkin’s lymphoma
14.7.5.4.11. Rhesus
disease Immunisation
14.7.5.4.12. Systemic
Lupus Erythematosus
14.7.5.4.13. Crohn's
Disease
14.7.5.4.14. Ulcerative
Colitis
14.7.5.4.15. Psoriasis
and Rheumatoid Arthritis
14.7.5.4.16. Cardiovascular
Disease
14.7.5.4.17. Others
14.7.5.5. Italy
Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By End Use
14.7.5.5.1. Hospitals
14.7.5.5.2. Clinics
14.7.5.5.3. Research
Institutes
14.7.5.5.4. Others
14.7.6. Nordic
Countries
14.7.6.1. Nordic
Countries Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By
Source
14.7.6.1.1. Murine
14.7.6.1.2. Chimeric
14.7.6.1.3. Humanized
14.7.6.1.4. Human
14.7.6.2. Nordic
Countries Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Type
14.7.6.2.1. Naked
Monoclonal Antibodies
14.7.6.2.2. Conjugated
Monoclonal Antibodies
14.7.6.2.3. Bispecific
Monoclonal Antibodies
14.7.6.2.4. Others
14.7.6.3. Nordic
Countries Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By
Clinical Trial Phases
14.7.6.3.1. Phase
0
14.7.6.3.2. Phase
I
14.7.6.3.3. Phase
II
14.7.6.3.4. Phase
III
14.7.6.3.5. Phase
IV
14.7.6.4. Nordic
Countries Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By
Application
14.7.6.4.1. Diagnostic
Testing
14.7.6.4.2. Autoimmune
Diseases
14.7.6.4.3. Cancer
Treatment
14.7.6.4.3.1. Breast
Cancer
14.7.6.4.3.2. Stomach
Cancer
14.7.6.4.3.3. Others
14.7.6.4.4. Pregnancy
Testing
14.7.6.4.5. Radioimmunodetection
(RID) of Cancer
14.7.6.4.6. Radioimmunotheraphy
(RIT) of Cancer
14.7.6.4.7. Viral
Disease Treatment
14.7.6.4.8. Identifying
Pathogens
14.7.6.4.9. Alzheimer’s
disease
14.7.6.4.10. Chronic
lymphocytic leukemia and non-Hodgkin’s lymphoma
14.7.6.4.11. Rhesus
disease Immunisation
14.7.6.4.12. Systemic
Lupus Erythematosus
14.7.6.4.13. Crohn's
Disease
14.7.6.4.14. Ulcerative
Colitis
14.7.6.4.15. Psoriasis
and Rheumatoid Arthritis
14.7.6.4.16. Cardiovascular
Disease
14.7.6.4.17. Others
14.7.6.5. Nordic
Countries Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By End
Use
14.7.6.5.1. Hospitals
14.7.6.5.2. Clinics
14.7.6.5.3. Research
Institutes
14.7.6.5.4. Others
14.7.6.6. Nordic
Countries Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By
Country
14.7.6.6.1. Denmark
14.7.6.6.2. Finland
14.7.6.6.3. Iceland
14.7.6.6.4. Sweden
14.7.6.6.5. Norway
14.7.7. Benelux
Union
14.7.7.1. Benelux
Union Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Source
14.7.7.1.1. Murine
14.7.7.1.2. Chimeric
14.7.7.1.3. Humanized
14.7.7.1.4. Human
14.7.7.2. Benelux
Union Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Type
14.7.7.2.1. Naked
Monoclonal Antibodies
14.7.7.2.2. Conjugated
Monoclonal Antibodies
14.7.7.2.3. Bispecific
Monoclonal Antibodies
14.7.7.2.4. Others
14.7.7.3. Benelux
Union Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Clinical
Trial Phases
14.7.7.3.1. Phase
0
14.7.7.3.2. Phase
I
14.7.7.3.3. Phase
II
14.7.7.3.4. Phase
III
14.7.7.3.5. Phase
IV
14.7.7.4. Benelux
Union Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By
Application
14.7.7.4.1. Diagnostic
Testing
14.7.7.4.2. Autoimmune
Diseases
14.7.7.4.3. Cancer
Treatment
14.7.7.4.3.1. Breast
Cancer
14.7.7.4.3.2. Stomach
Cancer
14.7.7.4.3.3. Others
14.7.7.4.4. Pregnancy
Testing
14.7.7.4.5. Radioimmunodetection
(RID) of Cancer
14.7.7.4.6. Radioimmunotheraphy
(RIT) of Cancer
14.7.7.4.7. Viral
Disease Treatment
14.7.7.4.8. Identifying
Pathogens
14.7.7.4.9. Alzheimer’s
disease
14.7.7.4.10. Chronic
lymphocytic leukemia and non-Hodgkin’s lymphoma
14.7.7.4.11. Rhesus
disease Immunisation
14.7.7.4.12. Systemic
Lupus Erythematosus
14.7.7.4.13. Crohn's
Disease
14.7.7.4.14. Ulcerative
Colitis
14.7.7.4.15. Psoriasis
and Rheumatoid Arthritis
14.7.7.4.16. Cardiovascular
Disease
14.7.7.4.17. Others
14.7.7.5. Benelux
Union Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By End Use
14.7.7.5.1. Hospitals
14.7.7.5.2. Clinics
14.7.7.5.3. Research
Institutes
14.7.7.5.4. Others
14.7.7.6. Benelux
Union Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Country
14.7.7.6.1. Belgium
14.7.7.6.2. The
Netherlands
14.7.7.6.3. Luxembourg
14.7.8. Rest of
Europe
14.7.8.1. Rest
of Europe Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By
Source
14.7.8.1.1. Murine
14.7.8.1.2. Chimeric
14.7.8.1.3. Humanized
14.7.8.1.4. Human
14.7.8.2. Rest
of Europe Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Type
14.7.8.2.1. Naked
Monoclonal Antibodies
14.7.8.2.2. Conjugated
Monoclonal Antibodies
14.7.8.2.3. Bispecific
Monoclonal Antibodies
14.7.8.2.4. Others
14.7.8.3. Rest
of Europe Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By
Clinical Trial Phases
14.7.8.3.1. Phase
0
14.7.8.3.2. Phase
I
14.7.8.3.3. Phase
II
14.7.8.3.4. Phase
III
14.7.8.3.5. Phase
IV
14.7.8.4. Rest
of Europe Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By
Application
14.7.8.4.1. Diagnostic
Testing
14.7.8.4.2. Autoimmune
Diseases
14.7.8.4.3. Cancer
Treatment
14.7.8.4.3.1. Breast
Cancer
14.7.8.4.3.2. Stomach
Cancer
14.7.8.4.3.3. Others
14.7.8.4.4. Pregnancy
Testing
14.7.8.4.5. Radioimmunodetection
(RID) of Cancer
14.7.8.4.6. Radioimmunotheraphy
(RIT) of Cancer
14.7.8.4.7. Viral
Disease Treatment
14.7.8.4.8. Identifying
Pathogens
14.7.8.4.9. Alzheimer’s
disease
14.7.8.4.10. Chronic
lymphocytic leukemia and non-Hodgkin’s lymphoma
14.7.8.4.11. Rhesus
disease Immunisation
14.7.8.4.12. Systemic
Lupus Erythematosus
14.7.8.4.13. Crohn's
Disease
14.7.8.4.14. Ulcerative
Colitis
14.7.8.4.15. Psoriasis
and Rheumatoid Arthritis
14.7.8.4.16. Cardiovascular
Disease
14.7.8.4.17. Others
14.7.8.5. Rest
of Europe Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By End
Use
14.7.8.5.1. Hospitals
14.7.8.5.2. Clinics
14.7.8.5.3. Research
Institutes
14.7.8.5.4. Others
14.8. Key Segment
for Channeling Investments
14.8.1. By
Country
14.8.2. By
Source
14.8.3. By Type
14.8.4. By
Clinical Trial Phases
14.8.5. By
Application
14.8.6. By End
Use
15. Asia
Pacific Monoclonal Antibodies Market Analysis and Forecasts, 2020 - 2028
15.1. Overview
15.1.1. Asia
Pacific Monoclonal Antibodies Market Revenue (US$ Mn)
15.2. Asia
Pacific Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Source
15.2.1. Murine
15.2.2. Chimeric
15.2.3. Humanized
15.2.4. Human
15.3. Asia
Pacific Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Type
15.3.1. Naked
Monoclonal Antibodies
15.3.2. Conjugated
Monoclonal Antibodies
15.3.3. Bispecific
Monoclonal Antibodies
15.3.4. Others
15.4. Asia
Pacific Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By
Clinical Trial Phases
15.4.1. Phase 0
15.4.2. Phase I
15.4.3. Phase
II
15.4.4. Phase
III
15.4.5. Phase
IV
15.5. Asia
Pacific Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By
Application
15.5.1. Diagnostic
Testing
15.5.2. Autoimmune
Diseases
15.5.3. Cancer
Treatment
15.5.3.1. Breast
Cancer
15.5.3.2. Stomach
Cancer
15.5.3.3. Others
15.5.4. Pregnancy
Testing
15.5.5. Radioimmunodetection
(RID) of Cancer
15.5.6. Radioimmunotheraphy
(RIT) of Cancer
15.5.7. Viral
Disease Treatment
15.5.8. Identifying
Pathogens
15.5.9. Alzheimer’s
disease
15.5.10. Chronic
lymphocytic leukemia and non-Hodgkin’s lymphoma
15.5.11. Rhesus
disease Immunisation
15.5.12. Systemic
Lupus Erythematosus
15.5.13. Crohn's
Disease
15.5.14. Ulcerative
Colitis
15.5.15. Psoriasis
and Rheumatoid Arthritis
15.5.16. Cardiovascular
Disease
15.5.17. Others
15.6. Asia
Pacific Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By End Use
15.6.1. Hospitals
15.6.2. Clinics
15.6.3. Research
Institutes
15.6.4. Others
15.7. Asia
Pacific Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Country
15.7.1. China
15.7.1.1. China
Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Source
15.7.1.1.1. Murine
15.7.1.1.2. Chimeric
15.7.1.1.3. Humanized
15.7.1.1.4. Human
15.7.1.2. China
Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Type
15.7.1.2.1. Naked
Monoclonal Antibodies
15.7.1.2.2. Conjugated
Monoclonal Antibodies
15.7.1.2.3. Bispecific
Monoclonal Antibodies
15.7.1.2.4. Others
15.7.1.3. China
Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Clinical Trial
Phases
15.7.1.3.1. Phase
0
15.7.1.3.2. Phase
I
15.7.1.3.3. Phase
II
15.7.1.3.4. Phase
III
15.7.1.3.5. Phase
IV
15.7.1.4. China
Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Application
15.7.1.4.1. Diagnostic
Testing
15.7.1.4.2. Autoimmune
Diseases
15.7.1.4.3. Cancer
Treatment
15.7.1.4.3.1. Breast
Cancer
15.7.1.4.3.2. Stomach
Cancer
15.7.1.4.3.3. Others
15.7.1.4.4. Pregnancy
Testing
15.7.1.4.5. Radioimmunodetection
(RID) of Cancer
15.7.1.4.6. Radioimmunotheraphy
(RIT) of Cancer
15.7.1.4.7. Viral
Disease Treatment
15.7.1.4.8. Identifying
Pathogens
15.7.1.4.9. Alzheimer’s
disease
15.7.1.4.10. Chronic
lymphocytic leukemia and non-Hodgkin’s lymphoma
15.7.1.4.11. Rhesus
disease Immunisation
15.7.1.4.12. Systemic
Lupus Erythematosus
15.7.1.4.13. Crohn's
Disease
15.7.1.4.14. Ulcerative
Colitis
15.7.1.4.15. Psoriasis
and Rheumatoid Arthritis
15.7.1.4.16. Cardiovascular
Disease
15.7.1.4.17. Others
15.7.1.5. China
Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By End Use
15.7.1.5.1. Hospitals
15.7.1.5.2. Clinics
15.7.1.5.3. Research
Institutes
15.7.1.5.4. Others
15.7.2. Japan
15.7.2.1. Japan
Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Source
15.7.2.1.1. Murine
15.7.2.1.2. Chimeric
15.7.2.1.3. Humanized
15.7.2.1.4. Human
15.7.2.2. Japan
Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Type
15.7.2.2.1. Naked
Monoclonal Antibodies
15.7.2.2.2. Conjugated
Monoclonal Antibodies
15.7.2.2.3. Bispecific
Monoclonal Antibodies
15.7.2.2.4. Others
15.7.2.3. Japan
Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Clinical Trial
Phases
15.7.2.3.1. Phase
0
15.7.2.3.2. Phase
I
15.7.2.3.3. Phase
II
15.7.2.3.4. Phase
III
15.7.2.3.5. Phase
IV
15.7.2.4. Japan
Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Application
15.7.2.4.1. Diagnostic
Testing
15.7.2.4.2. Autoimmune
Diseases
15.7.2.4.3. Cancer
Treatment
15.7.2.4.3.1. Breast
Cancer
15.7.2.4.3.2. Stomach
Cancer
15.7.2.4.3.3. Others
15.7.2.4.4. Pregnancy
Testing
15.7.2.4.5. Radioimmunodetection
(RID) of Cancer
15.7.2.4.6. Radioimmunotheraphy
(RIT) of Cancer
15.7.2.4.7. Viral
Disease Treatment
15.7.2.4.8. Identifying
Pathogens
15.7.2.4.9. Alzheimer’s
disease
15.7.2.4.10. Chronic
lymphocytic leukemia and non-Hodgkin’s lymphoma
15.7.2.4.11. Rhesus
disease Immunisation
15.7.2.4.12. Systemic
Lupus Erythematosus
15.7.2.4.13. Crohn's
Disease
15.7.2.4.14. Ulcerative
Colitis
15.7.2.4.15. Psoriasis
and Rheumatoid Arthritis
15.7.2.4.16. Cardiovascular
Disease
15.7.2.4.17. Others
15.7.2.5. Japan
Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By End Use
15.7.2.5.1. Hospitals
15.7.2.5.2. Clinics
15.7.2.5.3. Research
Institutes
15.7.2.5.4. Others
15.7.3. India
15.7.3.1. India
Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Source
15.7.3.1.1. Murine
15.7.3.1.2. Chimeric
15.7.3.1.3. Humanized
15.7.3.1.4. Human
15.7.3.2. India
Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Type
15.7.3.2.1. Naked
Monoclonal Antibodies
15.7.3.2.2. Conjugated
Monoclonal Antibodies
15.7.3.2.3. Bispecific
Monoclonal Antibodies
15.7.3.2.4. Others
15.7.3.3. India
Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Clinical Trial
Phases
15.7.3.3.1. Phase
0
15.7.3.3.2. Phase
I
15.7.3.3.3. Phase
II
15.7.3.3.4. Phase
III
15.7.3.3.5. Phase
IV
15.7.3.4. India
Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Application
15.7.3.4.1. Diagnostic
Testing
15.7.3.4.2. Autoimmune
Diseases
15.7.3.4.3. Cancer
Treatment
15.7.3.4.3.1. Breast
Cancer
15.7.3.4.3.2. Stomach
Cancer
15.7.3.4.3.3. Others
15.7.3.4.4. Pregnancy
Testing
15.7.3.4.5. Radioimmunodetection
(RID) of Cancer
15.7.3.4.6. Radioimmunotheraphy
(RIT) of Cancer
15.7.3.4.7. Viral
Disease Treatment
15.7.3.4.8. Identifying
Pathogens
15.7.3.4.9. Alzheimer’s
disease
15.7.3.4.10. Chronic
lymphocytic leukemia and non-Hodgkin’s lymphoma
15.7.3.4.11. Rhesus
disease Immunisation
15.7.3.4.12. Systemic
Lupus Erythematosus
15.7.3.4.13. Crohn's
Disease
15.7.3.4.14. Ulcerative
Colitis
15.7.3.4.15. Psoriasis
and Rheumatoid Arthritis
15.7.3.4.16. Cardiovascular
Disease
15.7.3.4.17. Others
15.7.3.5. India
Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By End Use
15.7.3.5.1. Hospitals
15.7.3.5.2. Clinics
15.7.3.5.3. Research
Institutes
15.7.3.5.4. Others
15.7.4. New
Zealand
15.7.4.1. New
Zealand Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Source
15.7.4.1.1. Murine
15.7.4.1.2. Chimeric
15.7.4.1.3. Humanized
15.7.4.1.4. Human
15.7.4.2. New
Zealand Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Type
15.7.4.2.1. Naked
Monoclonal Antibodies
15.7.4.2.2. Conjugated
Monoclonal Antibodies
15.7.4.2.3. Bispecific
Monoclonal Antibodies
15.7.4.2.4. Others
15.7.4.3. New
Zealand Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By
Clinical Trial Phases
15.7.4.3.1. Phase
0
15.7.4.3.2. Phase
I
15.7.4.3.3. Phase
II
15.7.4.3.4. Phase
III
15.7.4.3.5. Phase
IV
15.7.4.4. New
Zealand Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By
Application
15.7.4.4.1. Diagnostic
Testing
15.7.4.4.2. Autoimmune
Diseases
15.7.4.4.3. Cancer
Treatment
15.7.4.4.3.1. Breast
Cancer
15.7.4.4.3.2. Stomach
Cancer
15.7.4.4.3.3. Others
15.7.4.4.4. Pregnancy
Testing
15.7.4.4.5. Radioimmunodetection
(RID) of Cancer
15.7.4.4.6. Radioimmunotheraphy
(RIT) of Cancer
15.7.4.4.7. Viral
Disease Treatment
15.7.4.4.8. Identifying
Pathogens
15.7.4.4.9. Alzheimer’s
disease
15.7.4.4.10. Chronic
lymphocytic leukemia and non-Hodgkin’s lymphoma
15.7.4.4.11. Rhesus
disease Immunisation
15.7.4.4.12. Systemic
Lupus Erythematosus
15.7.4.4.13. Crohn's
Disease
15.7.4.4.14. Ulcerative
Colitis
15.7.4.4.15. Psoriasis
and Rheumatoid Arthritis
15.7.4.4.16. Cardiovascular
Disease
15.7.4.4.17. Others
15.7.4.5. New
Zealand Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By End Use
15.7.4.5.1. Hospitals
15.7.4.5.2. Clinics
15.7.4.5.3. Research
Institutes
15.7.4.5.4. Others
15.7.5. Australia
15.7.5.1. Australia
Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Source
15.7.5.1.1. Murine
15.7.5.1.2. Chimeric
15.7.5.1.3. Humanized
15.7.5.1.4. Human
15.7.5.2. Australia
Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Type
15.7.5.2.1. Naked
Monoclonal Antibodies
15.7.5.2.2. Conjugated
Monoclonal Antibodies
15.7.5.2.3. Bispecific
Monoclonal Antibodies
15.7.5.2.4. Others
15.7.5.3. Australia
Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Clinical Trial
Phases
15.7.5.3.1. Phase
0
15.7.5.3.2. Phase
I
15.7.5.3.3. Phase
II
15.7.5.3.4. Phase
III
15.7.5.3.5. Phase
IV
15.7.5.4. Australia
Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Application
15.7.5.4.1. Diagnostic
Testing
15.7.5.4.2. Autoimmune
Diseases
15.7.5.4.3. Cancer
Treatment
15.7.5.4.3.1. Breast
Cancer
15.7.5.4.3.2. Stomach
Cancer
15.7.5.4.3.3. Others
15.7.5.4.4. Pregnancy
Testing
15.7.5.4.5. Radioimmunodetection
(RID) of Cancer
15.7.5.4.6. Radioimmunotheraphy
(RIT) of Cancer
15.7.5.4.7. Viral
Disease Treatment
15.7.5.4.8. Identifying
Pathogens
15.7.5.4.9. Alzheimer’s
disease
15.7.5.4.10. Chronic
lymphocytic leukemia and non-Hodgkin’s lymphoma
15.7.5.4.11. Rhesus
disease Immunisation
15.7.5.4.12. Systemic
Lupus Erythematosus
15.7.5.4.13. Crohn's
Disease
15.7.5.4.14. Ulcerative
Colitis
15.7.5.4.15. Psoriasis
and Rheumatoid Arthritis
15.7.5.4.16. Cardiovascular
Disease
15.7.5.4.17. Others
15.7.5.5. Australia
Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By End Use
15.7.5.5.1. Hospitals
15.7.5.5.2. Clinics
15.7.5.5.3. Research
Institutes
15.7.5.5.4. Others
15.7.6. South
Korea
15.7.6.1. South
Korea Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Source
15.7.6.1.1. Murine
15.7.6.1.2. Chimeric
15.7.6.1.3. Humanized
15.7.6.1.4. Human
15.7.6.2. South
Korea Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Type
15.7.6.2.1. Naked
Monoclonal Antibodies
15.7.6.2.2. Conjugated
Monoclonal Antibodies
15.7.6.2.3. Bispecific
Monoclonal Antibodies
15.7.6.2.4. Others
15.7.6.3. South
Korea Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Clinical
Trial Phases
15.7.6.3.1. Phase
0
15.7.6.3.2. Phase
I
15.7.6.3.3. Phase
II
15.7.6.3.4. Phase
III
15.7.6.3.5. Phase
IV
15.7.6.4. South
Korea Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By
Application
15.7.6.4.1. Diagnostic
Testing
15.7.6.4.2. Autoimmune
Diseases
15.7.6.4.3. Cancer
Treatment
15.7.6.4.3.1. Breast
Cancer
15.7.6.4.3.2. Stomach
Cancer
15.7.6.4.3.3. Others
15.7.6.4.4. Pregnancy
Testing
15.7.6.4.5. Radioimmunodetection
(RID) of Cancer
15.7.6.4.6. Radioimmunotheraphy
(RIT) of Cancer
15.7.6.4.7. Viral
Disease Treatment
15.7.6.4.8. Identifying
Pathogens
15.7.6.4.9. Alzheimer’s
disease
15.7.6.4.10. Chronic
lymphocytic leukemia and non-Hodgkin’s lymphoma
15.7.6.4.11. Rhesus
disease Immunisation
15.7.6.4.12. Systemic
Lupus Erythematosus
15.7.6.4.13. Crohn's
Disease
15.7.6.4.14. Ulcerative
Colitis
15.7.6.4.15. Psoriasis
and Rheumatoid Arthritis
15.7.6.4.16. Cardiovascular
Disease
15.7.6.4.17. Others
15.7.6.5. South
Korea Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By End Use
15.7.6.5.1. Hospitals
15.7.6.5.2. Clinics
15.7.6.5.3. Research
Institutes
15.7.6.5.4. Others
15.7.7. Southeast
Asia
15.7.7.1. Southeast
Asia Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Source
15.7.7.1.1. Murine
15.7.7.1.2. Chimeric
15.7.7.1.3. Humanized
15.7.7.1.4. Human
15.7.7.2. Southeast
Asia Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Type
15.7.7.2.1. Naked
Monoclonal Antibodies
15.7.7.2.2. Conjugated
Monoclonal Antibodies
15.7.7.2.3. Bispecific
Monoclonal Antibodies
15.7.7.2.4. Others
15.7.7.3. Southeast
Asia Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Clinical
Trial Phases
15.7.7.3.1. Phase
0
15.7.7.3.2. Phase
I
15.7.7.3.3. Phase
II
15.7.7.3.4. Phase
III
15.7.7.3.5. Phase
IV
15.7.7.4. Southeast
Asia Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By
Application
15.7.7.4.1. Diagnostic
Testing
15.7.7.4.2. Autoimmune
Diseases
15.7.7.4.3. Cancer
Treatment
15.7.7.4.3.1. Breast
Cancer
15.7.7.4.3.2. Stomach
Cancer
15.7.7.4.3.3. Others
15.7.7.4.4. Pregnancy
Testing
15.7.7.4.5. Radioimmunodetection
(RID) of Cancer
15.7.7.4.6. Radioimmunotheraphy
(RIT) of Cancer
15.7.7.4.7. Viral
Disease Treatment
15.7.7.4.8. Identifying
Pathogens
15.7.7.4.9. Alzheimer’s
disease
15.7.7.4.10. Chronic
lymphocytic leukemia and non-Hodgkin’s lymphoma
15.7.7.4.11. Rhesus
disease Immunisation
15.7.7.4.12. Systemic
Lupus Erythematosus
15.7.7.4.13. Crohn's
Disease
15.7.7.4.14. Ulcerative
Colitis
15.7.7.4.15. Psoriasis
and Rheumatoid Arthritis
15.7.7.4.16. Cardiovascular
Disease
15.7.7.4.17. Others
15.7.7.5. Southeast
Asia Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By End Use
15.7.7.5.1. Hospitals
15.7.7.5.2. Clinics
15.7.7.5.3. Research
Institutes
15.7.7.5.4. Others
15.7.7.6. Southeast
Asia Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Country
15.7.7.6.1. Indonesia
15.7.7.6.2. Thailand
15.7.7.6.3. Malaysia
15.7.7.6.4. Singapore
15.7.7.6.5. Rest
of Southeast Asia
15.7.8. Rest of
Asia Pacific
15.7.8.1. Rest
of Asia Pacific Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By
Source
15.7.8.1.1. Murine
15.7.8.1.2. Chimeric
15.7.8.1.3. Humanized
15.7.8.1.4. Human
15.7.8.2. Rest
of Asia Pacific Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By
Type
15.7.8.2.1. Naked
Monoclonal Antibodies
15.7.8.2.2. Conjugated
Monoclonal Antibodies
15.7.8.2.3. Bispecific
Monoclonal Antibodies
15.7.8.2.4. Others
15.7.8.3. Rest
of Asia Pacific Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By
Clinical Trial Phases
15.7.8.3.1. Phase
0
15.7.8.3.2. Phase
I
15.7.8.3.3. Phase
II
15.7.8.3.4. Phase
III
15.7.8.3.5. Phase
IV
15.7.8.4. Rest
of Asia Pacific Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By
Application
15.7.8.4.1. Diagnostic
Testing
15.7.8.4.2. Autoimmune
Diseases
15.7.8.4.3. Cancer
Treatment
15.7.8.4.3.1. Breast
Cancer
15.7.8.4.3.2. Stomach
Cancer
15.7.8.4.3.3. Others
15.7.8.4.4. Pregnancy
Testing
15.7.8.4.5. Radioimmunodetection
(RID) of Cancer
15.7.8.4.6. Radioimmunotheraphy
(RIT) of Cancer
15.7.8.4.7. Viral
Disease Treatment
15.7.8.4.8. Identifying
Pathogens
15.7.8.4.9. Alzheimer’s
disease
15.7.8.4.10. Chronic
lymphocytic leukemia and non-Hodgkin’s lymphoma
15.7.8.4.11. Rhesus
disease Immunisation
15.7.8.4.12. Systemic
Lupus Erythematosus
15.7.8.4.13. Crohn's
Disease
15.7.8.4.14. Ulcerative
Colitis
15.7.8.4.15. Psoriasis
and Rheumatoid Arthritis
15.7.8.4.16. Cardiovascular
Disease
15.7.8.4.17. Others
15.7.8.5. Rest
of Asia Pacific Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By
End Use
15.7.8.5.1. Hospitals
15.7.8.5.2. Clinics
15.7.8.5.3. Research
Institutes
15.7.8.5.4. Others
15.8. Key
Segment for Channeling Investments
15.8.1. By
Country
15.8.2. By
Source
15.8.3. By Type
15.8.4. By
Clinical Trial Phases
15.8.5. By
Application
15.8.6. By End
Use
16. Middle
East and Africa Monoclonal Antibodies Market Analysis and Forecasts, 2020 -
2028
16.1. Overview
16.1.1. Middle
East and Africa Monoclonal Antibodies Market Revenue (US$ Mn)
16.2. Middle
East and Africa Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By
Source
16.2.1. Murine
16.2.2. Chimeric
16.2.3. Humanized
16.2.4. Human
16.3. Middle
East and Africa Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By
Type
16.3.1. Naked
Monoclonal Antibodies
16.3.2. Conjugated
Monoclonal Antibodies
16.3.3. Bispecific
Monoclonal Antibodies
16.3.4. Others
16.4. Middle
East and Africa Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By
Clinical Trial Phases
16.4.1. Phase 0
16.4.2. Phase I
16.4.3. Phase
II
16.4.4. Phase
III
16.4.5. Phase
IV
16.5. Middle
East and Africa Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By
Application
16.5.1. Diagnostic
Testing
16.5.2. Autoimmune
Diseases
16.5.3. Cancer
Treatment
16.5.3.1. Breast
Cancer
16.5.3.2. Stomach
Cancer
16.5.3.3. Others
16.5.4. Pregnancy
Testing
16.5.5. Radioimmunodetection
(RID) of Cancer
16.5.6. Radioimmunotheraphy
(RIT) of Cancer
16.5.7. Viral
Disease Treatment
16.5.8. Identifying
Pathogens
16.5.9. Alzheimer’s
disease
16.5.10. Chronic
lymphocytic leukemia and non-Hodgkin’s lymphoma
16.5.11. Rhesus
disease Immunisation
16.5.12. Systemic
Lupus Erythematosus
16.5.13. Crohn's
Disease
16.5.14. Ulcerative
Colitis
16.5.15. Psoriasis
and Rheumatoid Arthritis
16.5.16. Cardiovascular
Disease
16.5.17. Others
16.6. Middle
East and Africa Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By
End Use
16.6.1. Hospitals
16.6.2. Clinics
16.6.3. Research
Institutes
16.6.4. Others
16.7. Middle
East and Africa Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By
Country
16.7.1. Saudi
Arabia
16.7.1.1. Saudi
Arabia Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Source
16.7.1.1.1. Murine
16.7.1.1.2. Chimeric
16.7.1.1.3. Humanized
16.7.1.1.4. Human
16.7.1.2. Saudi
Arabia Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Type
16.7.1.2.1. Naked
Monoclonal Antibodies
16.7.1.2.2. Conjugated
Monoclonal Antibodies
16.7.1.2.3. Bispecific
Monoclonal Antibodies
16.7.1.2.4. Others
16.7.1.3. Saudi
Arabia Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Clinical
Trial Phases
16.7.1.3.1. Phase
0
16.7.1.3.2. Phase
I
16.7.1.3.3. Phase
II
16.7.1.3.4. Phase
III
16.7.1.3.5. Phase
IV
16.7.1.4. Saudi
Arabia Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By
Application
16.7.1.4.1. Diagnostic
Testing
16.7.1.4.2. Autoimmune
Diseases
16.7.1.4.3. Cancer
Treatment
16.7.1.4.3.1. Breast
Cancer
16.7.1.4.3.2. Stomach
Cancer
16.7.1.4.3.3. Others
16.7.1.4.4. Pregnancy
Testing
16.7.1.4.5. Radioimmunodetection
(RID) of Cancer
16.7.1.4.6. Radioimmunotheraphy
(RIT) of Cancer
16.7.1.4.7. Viral
Disease Treatment
16.7.1.4.8. Identifying
Pathogens
16.7.1.4.9. Alzheimer’s
disease
16.7.1.4.10. Chronic
lymphocytic leukemia and non-Hodgkin’s lymphoma
16.7.1.4.11. Rhesus
disease Immunisation
16.7.1.4.12. Systemic
Lupus Erythematosus
16.7.1.4.13. Crohn's
Disease
16.7.1.4.14. Ulcerative
Colitis
16.7.1.4.15. Psoriasis
and Rheumatoid Arthritis
16.7.1.4.16. Cardiovascular
Disease
16.7.1.4.17. Others
16.7.1.5. Saudi
Arabia Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By End Use
16.7.1.5.1. Hospitals
16.7.1.5.2. Clinics
16.7.1.5.3. Research
Institutes
16.7.1.5.4. Others
16.7.2. UAE
16.7.2.1. UAE
Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Source
16.7.2.1.1. Murine
16.7.2.1.2. Chimeric
16.7.2.1.3. Humanized
16.7.2.1.4. Human
16.7.2.2. UAE
Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Type
16.7.2.2.1. Naked
Monoclonal Antibodies
16.7.2.2.2. Conjugated
Monoclonal Antibodies
16.7.2.2.3. Bispecific
Monoclonal Antibodies
16.7.2.2.4. Others
16.7.2.3. UAE
Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Clinical Trial
Phases
16.7.2.3.1. Phase
0
16.7.2.3.2. Phase
I
16.7.2.3.3. Phase
II
16.7.2.3.4. Phase
III
16.7.2.3.5. Phase
IV
16.7.2.4. UAE
Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Application
16.7.2.4.1. Diagnostic
Testing
16.7.2.4.2. Autoimmune
Diseases
16.7.2.4.3. Cancer
Treatment
16.7.2.4.3.1. Breast
Cancer
16.7.2.4.3.2. Stomach
Cancer
16.7.2.4.3.3. Others
16.7.2.4.4. Pregnancy
Testing
16.7.2.4.5. Radioimmunodetection
(RID) of Cancer
16.7.2.4.6. Radioimmunotheraphy
(RIT) of Cancer
16.7.2.4.7. Viral
Disease Treatment
16.7.2.4.8. Identifying
Pathogens
16.7.2.4.9. Alzheimer’s
disease
16.7.2.4.10. Chronic
lymphocytic leukemia and non-Hodgkin’s lymphoma
16.7.2.4.11. Rhesus
disease Immunisation
16.7.2.4.12. Systemic
Lupus Erythematosus
16.7.2.4.13. Crohn's
Disease
16.7.2.4.14. Ulcerative
Colitis
16.7.2.4.15. Psoriasis
and Rheumatoid Arthritis
16.7.2.4.16. Cardiovascular
Disease
16.7.2.4.17. Others
16.7.2.5. UAE
Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By End Use
16.7.2.5.1. Hospitals
16.7.2.5.2. Clinics
16.7.2.5.3. Research
Institutes
16.7.2.5.4. Others
16.7.3. Egypt
16.7.3.1. Egypt
Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Source
16.7.3.1.1. Murine
16.7.3.1.2. Chimeric
16.7.3.1.3. Humanized
16.7.3.1.4. Human
16.7.3.2. Egypt
Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Type
16.7.3.2.1. Naked
Monoclonal Antibodies
16.7.3.2.2. Conjugated
Monoclonal Antibodies
16.7.3.2.3. Bispecific
Monoclonal Antibodies
16.7.3.2.4. Others
16.7.3.3. Egypt
Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Clinical Trial
Phases
16.7.3.3.1. Phase
0
16.7.3.3.2. Phase
I
16.7.3.3.3. Phase
II
16.7.3.3.4. Phase
III
16.7.3.3.5. Phase
IV
16.7.3.4. Egypt
Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Application
16.7.3.4.1. Diagnostic
Testing
16.7.3.4.2. Autoimmune
Diseases
16.7.3.4.3. Cancer
Treatment
16.7.3.4.3.1. Breast
Cancer
16.7.3.4.3.2. Stomach
Cancer
16.7.3.4.3.3. Others
16.7.3.4.4. Pregnancy
Testing
16.7.3.4.5. Radioimmunodetection
(RID) of Cancer
16.7.3.4.6. Radioimmunotheraphy
(RIT) of Cancer
16.7.3.4.7. Viral
Disease Treatment
16.7.3.4.8. Identifying
Pathogens
16.7.3.4.9. Alzheimer’s
disease
16.7.3.4.10. Chronic
lymphocytic leukemia and non-Hodgkin’s lymphoma
16.7.3.4.11. Rhesus
disease Immunisation
16.7.3.4.12. Systemic
Lupus Erythematosus
16.7.3.4.13. Crohn's
Disease
16.7.3.4.14. Ulcerative
Colitis
16.7.3.4.15. Psoriasis
and Rheumatoid Arthritis
16.7.3.4.16. Cardiovascular
Disease
16.7.3.4.17. Others
16.7.3.5. Egypt
Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By End Use
16.7.3.5.1. Hospitals
16.7.3.5.2. Clinics
16.7.3.5.3. Research
Institutes
16.7.3.5.4. Others
16.7.4. Kuwait
16.7.4.1. Kuwait
Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Source
16.7.4.1.1. Murine
16.7.4.1.2. Chimeric
16.7.4.1.3. Humanized
16.7.4.1.4. Human
16.7.4.2. Kuwait
Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Type
16.7.4.2.1. Naked
Monoclonal Antibodies
16.7.4.2.2. Conjugated
Monoclonal Antibodies
16.7.4.2.3. Bispecific
Monoclonal Antibodies
16.7.4.2.4. Others
16.7.4.3. Kuwait
Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Clinical Trial
Phases
16.7.4.3.1. Phase
0
16.7.4.3.2. Phase
I
16.7.4.3.3. Phase
II
16.7.4.3.4. Phase
III
16.7.4.3.5. Phase
IV
16.7.4.4. Kuwait
Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Application
16.7.4.4.1. Diagnostic
Testing
16.7.4.4.2. Autoimmune
Diseases
16.7.4.4.3. Cancer
Treatment
16.7.4.4.3.1. Breast
Cancer
16.7.4.4.3.2. Stomach
Cancer
16.7.4.4.3.3. Others
16.7.4.4.4. Pregnancy
Testing
16.7.4.4.5. Radioimmunodetection
(RID) of Cancer
16.7.4.4.6. Radioimmunotheraphy
(RIT) of Cancer
16.7.4.4.7. Viral
Disease Treatment
16.7.4.4.8. Identifying
Pathogens
16.7.4.4.9. Alzheimer’s
disease
16.7.4.4.10. Chronic
lymphocytic leukemia and non-Hodgkin’s lymphoma
16.7.4.4.11. Rhesus
disease Immunisation
16.7.4.4.12. Systemic
Lupus Erythematosus
16.7.4.4.13. Crohn's
Disease
16.7.4.4.14. Ulcerative
Colitis
16.7.4.4.15. Psoriasis
and Rheumatoid Arthritis
16.7.4.4.16. Cardiovascular
Disease
16.7.4.4.17. Others
16.7.4.5. Kuwait
Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By End Use
16.7.4.5.1. Hospitals
16.7.4.5.2. Clinics
16.7.4.5.3. Research
Institutes
16.7.4.5.4. Others
16.7.5. South
Africa
16.7.5.1. South
Africa Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Source
16.7.5.1.1. Murine
16.7.5.1.2. Chimeric
16.7.5.1.3. Humanized
16.7.5.1.4. Human
16.7.5.2. South
Africa Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Type
16.7.5.2.1. Naked
Monoclonal Antibodies
16.7.5.2.2. Conjugated
Monoclonal Antibodies
16.7.5.2.3. Bispecific
Monoclonal Antibodies
16.7.5.2.4. Others
16.7.5.3. South
Africa Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Clinical
Trial Phases
16.7.5.3.1. Phase
0
16.7.5.3.2. Phase
I
16.7.5.3.3. Phase
II
16.7.5.3.4. Phase
III
16.7.5.3.5. Phase
IV
16.7.5.4. South
Africa Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By
Application
16.7.5.4.1. Diagnostic
Testing
16.7.5.4.2. Autoimmune
Diseases
16.7.5.4.3. Cancer
Treatment
16.7.5.4.3.1. Breast
Cancer
16.7.5.4.3.2. Stomach
Cancer
16.7.5.4.3.3. Others
16.7.5.4.4. Pregnancy
Testing
16.7.5.4.5. Radioimmunodetection
(RID) of Cancer
16.7.5.4.6. Radioimmunotheraphy
(RIT) of Cancer
16.7.5.4.7. Viral
Disease Treatment
16.7.5.4.8. Identifying
Pathogens
16.7.5.4.9. Alzheimer’s
disease
16.7.5.4.10. Chronic
lymphocytic leukemia and non-Hodgkin’s lymphoma
16.7.5.4.11. Rhesus
disease Immunisation
16.7.5.4.12. Systemic
Lupus Erythematosus
16.7.5.4.13. Crohn's
Disease
16.7.5.4.14. Ulcerative
Colitis
16.7.5.4.15. Psoriasis
and Rheumatoid Arthritis
16.7.5.4.16. Cardiovascular
Disease
16.7.5.4.17. Others
16.7.5.5. South
Africa Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By End Use
16.7.5.5.1. Hospitals
16.7.5.5.2. Clinics
16.7.5.5.3. Research
Institutes
16.7.5.5.4. Others
16.7.6. Rest of
Middle East & Africa
16.7.6.1. Rest
of Middle East & Africa Monoclonal Antibodies Market Revenue (US$ Mn) and
Forecasts, By Source
16.7.6.1.1. Murine
16.7.6.1.2. Chimeric
16.7.6.1.3. Humanized
16.7.6.1.4. Human
16.7.6.2. Rest
of Middle East & Africa Monoclonal Antibodies Market Revenue (US$ Mn) and
Forecasts, By Type
16.7.6.2.1. Naked
Monoclonal Antibodies
16.7.6.2.2. Conjugated
Monoclonal Antibodies
16.7.6.2.3. Bispecific
Monoclonal Antibodies
16.7.6.2.4. Others
16.7.6.3. Rest
of Middle East & Africa Monoclonal Antibodies Market Revenue (US$ Mn) and
Forecasts, By Clinical Trial Phases
16.7.6.3.1. Phase
0
16.7.6.3.2. Phase
I
16.7.6.3.3. Phase
II
16.7.6.3.4. Phase
III
16.7.6.3.5. Phase
IV
16.7.6.4. Rest
of Middle East & Africa Monoclonal Antibodies Market Revenue (US$ Mn) and
Forecasts, By Application
16.7.6.4.1. Diagnostic
Testing
16.7.6.4.2. Autoimmune
Diseases
16.7.6.4.3. Cancer
Treatment
16.7.6.4.3.1. Breast
Cancer
16.7.6.4.3.2. Stomach
Cancer
16.7.6.4.3.3. Others
16.7.6.4.4. Pregnancy
Testing
16.7.6.4.5. Radioimmunodetection
(RID) of Cancer
16.7.6.4.6. Radioimmunotheraphy
(RIT) of Cancer
16.7.6.4.7. Viral
Disease Treatment
16.7.6.4.8. Identifying
Pathogens
16.7.6.4.9. Alzheimer’s
disease
16.7.6.4.10. Chronic
lymphocytic leukemia and non-Hodgkin’s lymphoma
16.7.6.4.11. Rhesus
disease Immunisation
16.7.6.4.12. Systemic
Lupus Erythematosus
16.7.6.4.13. Crohn's
Disease
16.7.6.4.14. Ulcerative
Colitis
16.7.6.4.15. Psoriasis
and Rheumatoid Arthritis
16.7.6.4.16. Cardiovascular
Disease
16.7.6.4.17. Others
16.7.6.5. Rest
of Middle East & Africa Monoclonal Antibodies Market Revenue (US$ Mn) and
Forecasts, By End Use
16.7.6.5.1. Hospitals
16.7.6.5.2. Clinics
16.7.6.5.3. Research
Institutes
16.7.6.5.4. Others
16.8. Key
Segment for Channeling Investments
16.8.1. By
Country
16.8.2. By
Source
16.8.3. By Type
16.8.4. By
Clinical Trial Phases
16.8.5. By
Application
16.8.6. By End
Use
17. Latin
America Monoclonal Antibodies Market Analysis and Forecasts, 2020 - 2028
17.1. Overview
17.1.1. Latin
America Monoclonal Antibodies Market Revenue (US$ Mn)
17.2. Latin
America Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Source
17.2.1. Murine
17.2.2. Chimeric
17.2.3. Humanized
17.2.4. Human
17.3. Latin
America Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Type
17.3.1. Naked
Monoclonal Antibodies
17.3.2. Conjugated
Monoclonal Antibodies
17.3.3. Bispecific
Monoclonal Antibodies
17.3.4. Others
17.4. Latin
America Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By
Clinical Trial Phases
17.4.1. Phase 0
17.4.2. Phase I
17.4.3. Phase
II
17.4.4. Phase
III
17.4.5. Phase
IV
17.5. Latin
America Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By
Application
17.5.1. Diagnostic
Testing
17.5.2. Autoimmune
Diseases
17.5.3. Cancer
Treatment
17.5.3.1. Breast
Cancer
17.5.3.2. Stomach
Cancer
17.5.3.3. Others
17.5.4. Pregnancy
Testing
17.5.5. Radioimmunodetection
(RID) of Cancer
17.5.6. Radioimmunotheraphy
(RIT) of Cancer
17.5.7. Viral
Disease Treatment
17.5.8. Identifying
Pathogens
17.5.9. Alzheimer’s
disease
17.5.10. Chronic
lymphocytic leukemia and non-Hodgkin’s lymphoma
17.5.11. Rhesus
disease Immunisation
17.5.12. Systemic
Lupus Erythematosus
17.5.13. Crohn's
Disease
17.5.14. Ulcerative
Colitis
17.5.15. Psoriasis
and Rheumatoid Arthritis
17.5.16. Cardiovascular
Disease
17.5.17. Others
17.6. Latin
America Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By End Use
17.6.1. Hospitals
17.6.2. Clinics
17.6.3. Research
Institutes
17.6.4. Others
17.7. Latin
America Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Country
17.7.1. Brazil
17.7.1.1. Brazil
Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Source
17.7.1.1.1. Murine
17.7.1.1.2. Chimeric
17.7.1.1.3. Humanized
17.7.1.1.4. Human
17.7.1.2. Brazil
Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Type
17.7.1.2.1. Naked
Monoclonal Antibodies
17.7.1.2.2. Conjugated
Monoclonal Antibodies
17.7.1.2.3. Bispecific
Monoclonal Antibodies
17.7.1.2.4. Others
17.7.1.3. Brazil
Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Clinical Trial
Phases
17.7.1.3.1. Phase
0
17.7.1.3.2. Phase
I
17.7.1.3.3. Phase
II
17.7.1.3.4. Phase
III
17.7.1.3.5. Phase
IV
17.7.1.4. Brazil
Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Application
17.7.1.4.1. Diagnostic
Testing
17.7.1.4.2. Autoimmune
Diseases
17.7.1.4.3. Cancer
Treatment
17.7.1.4.3.1. Breast
Cancer
17.7.1.4.3.2. Stomach
Cancer
17.7.1.4.3.3. Others
17.7.1.4.4. Pregnancy
Testing
17.7.1.4.5. Radioimmunodetection
(RID) of Cancer
17.7.1.4.6. Radioimmunotheraphy
(RIT) of Cancer
17.7.1.4.7. Viral
Disease Treatment
17.7.1.4.8. Identifying
Pathogens
17.7.1.4.9. Alzheimer’s
disease
17.7.1.4.10. Chronic
lymphocytic leukemia and non-Hodgkin’s lymphoma
17.7.1.4.11. Rhesus
disease Immunisation
17.7.1.4.12. Systemic
Lupus Erythematosus
17.7.1.4.13. Crohn's
Disease
17.7.1.4.14. Ulcerative
Colitis
17.7.1.4.15. Psoriasis
and Rheumatoid Arthritis
17.7.1.4.16. Cardiovascular
Disease
17.7.1.4.17. Others
17.7.1.5. Brazil
Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By End Use
17.7.1.5.1. Hospitals
17.7.1.5.2. Clinics
17.7.1.5.3. Research
Institutes
17.7.1.5.4. Others
17.7.2. Argentina
17.7.2.1. Argentina
Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Source
17.7.2.1.1. Murine
17.7.2.1.2. Chimeric
17.7.2.1.3. Humanized
17.7.2.1.4. Human
17.7.2.2. Argentina
Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Type
17.7.2.2.1. Naked
Monoclonal Antibodies
17.7.2.2.2. Conjugated
Monoclonal Antibodies
17.7.2.2.3. Bispecific
Monoclonal Antibodies
17.7.2.2.4. Others
17.7.2.3. Argentina
Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Clinical Trial
Phases
17.7.2.3.1. Phase
0
17.7.2.3.2. Phase
I
17.7.2.3.3. Phase
II
17.7.2.3.4. Phase
III
17.7.2.3.5. Phase
IV
17.7.2.4. Argentina
Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By Application
17.7.2.4.1. Diagnostic
Testing
17.7.2.4.2. Autoimmune
Diseases
17.7.2.4.3. Cancer
Treatment
17.7.2.4.3.1. Breast
Cancer
17.7.2.4.3.2. Stomach
Cancer
17.7.2.4.3.3. Others
17.7.2.4.4. Pregnancy
Testing
17.7.2.4.5. Radioimmunodetection
(RID) of Cancer
17.7.2.4.6. Radioimmunotheraphy
(RIT) of Cancer
17.7.2.4.7. Viral
Disease Treatment
17.7.2.4.8. Identifying
Pathogens
17.7.2.4.9. Alzheimer’s
disease
17.7.2.4.10. Chronic
lymphocytic leukemia and non-Hodgkin’s lymphoma
17.7.2.4.11. Rhesus
disease Immunisation
17.7.2.4.12. Systemic
Lupus Erythematosus
17.7.2.4.13. Crohn's
Disease
17.7.2.4.14. Ulcerative
Colitis
17.7.2.4.15. Psoriasis
and Rheumatoid Arthritis
17.7.2.4.16. Cardiovascular
Disease
17.7.2.4.17. Others
17.7.2.5. Argentina
Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts, By End Use
17.7.2.5.1. Hospitals
17.7.2.5.2. Clinics
17.7.2.5.3. Research
Institutes
17.7.2.5.4. Others
17.7.3. Rest of
Latin America
17.7.3.1. Rest
of Latin America Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts,
By Source
17.7.3.1.1. Murine
17.7.3.1.2. Chimeric
17.7.3.1.3. Humanized
17.7.3.1.4. Human
17.7.3.2. Rest
of Latin America Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts,
By Type
17.7.3.2.1. Naked
Monoclonal Antibodies
17.7.3.2.2. Conjugated
Monoclonal Antibodies
17.7.3.2.3. Bispecific
Monoclonal Antibodies
17.7.3.2.4. Others
17.7.3.3. Rest
of Latin America Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts,
By Clinical Trial Phases
17.7.3.3.1. Phase
0
17.7.3.3.2. Phase
I
17.7.3.3.3. Phase
II
17.7.3.3.4. Phase
III
17.7.3.3.5. Phase
IV
17.7.3.4. Rest
of Latin America Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts,
By Application
17.7.3.4.1. Diagnostic
Testing
17.7.3.4.2. Autoimmune
Diseases
17.7.3.4.3. Cancer
Treatment
17.7.3.4.3.1. Breast
Cancer
17.7.3.4.3.2. Stomach
Cancer
17.7.3.4.3.3. Others
17.7.3.4.4. Pregnancy
Testing
17.7.3.4.5. Radioimmunodetection
(RID) of Cancer
17.7.3.4.6. Radioimmunotheraphy
(RIT) of Cancer
17.7.3.4.7. Viral
Disease Treatment
17.7.3.4.8. Identifying
Pathogens
17.7.3.4.9. Alzheimer’s
disease
17.7.3.4.10. Chronic
lymphocytic leukemia and non-Hodgkin’s lymphoma
17.7.3.4.11. Rhesus
disease Immunisation
17.7.3.4.12. Systemic
Lupus Erythematosus
17.7.3.4.13. Crohn's
Disease
17.7.3.4.14. Ulcerative
Colitis
17.7.3.4.15. Psoriasis
and Rheumatoid Arthritis
17.7.3.4.16. Cardiovascular
Disease
17.7.3.4.17. Others
17.7.3.5. Rest
of Latin America Monoclonal Antibodies Market Revenue (US$ Mn) and Forecasts,
By End Use
17.7.3.5.1. Hospitals
17.7.3.5.2. Clinics
17.7.3.5.3. Research
Institutes
17.7.3.5.4. Others
17.8. Key
Segment for Channeling Investments
17.8.1. By
Country
17.8.2. By
Source
17.8.3. By Type
17.8.4. By
Clinical Trial Phases
17.8.5. By
Application
17.8.6. By End
Use
18. Competitive
Benchmarking
18.1. Market
Share Analysis, 2019
18.2. Global
Presence and Growth Strategies
18.2.1. Mergers
and Acquisitions
18.2.2. Product
Launches
18.2.3. Investments
Trends
18.2.4. R&D
Initiatives
19. Player
Profiles
19.1. AbbVie
Inc.
19.1.1. Company
Details
19.1.2. Company
Overview
19.1.3. Product
Offerings
19.1.4. Key
Developments
19.1.5. Financial
Analysis
19.1.6. SWOT
Analysis
19.1.7. Business
Strategies
19.2. Alexion
Pharmaceuticals, Inc.
19.2.1. Company
Details
19.2.2. Company
Overview
19.2.3. Product
Offerings
19.2.4. Key
Developments
19.2.5. Financial
Analysis
19.2.6. SWOT
Analysis
19.2.7. Business
Strategies
19.3. Amgen
Inc.
19.3.1. Company
Details
19.3.2. Company
Overview
19.3.3. Product
Offerings
19.3.4. Key
Developments
19.3.5. Financial
Analysis
19.3.6. SWOT
Analysis
19.3.7. Business
Strategies
19.4. Bristol-Myers
Squibb Company
19.4.1. Company
Details
19.4.2. Company
Overview
19.4.3. Product
Offerings
19.4.4. Key
Developments
19.4.5. Financial
Analysis
19.4.6. SWOT
Analysis
19.4.7. Business
Strategies
19.5. DAIICHI
SANKYO COMPANY, LIMITED
19.5.1. Company
Details
19.5.2. Company
Overview
19.5.3. Product
Offerings
19.5.4. Key
Developments
19.5.5. Financial
Analysis
19.5.6. SWOT
Analysis
19.5.7. Business
Strategies
19.6. Eli Lilly
& Co. (acquired ImClone Systems, Inc.)
19.6.1. Company
Details
19.6.2. Company
Overview
19.6.3. Product
Offerings
19.6.4. Key
Developments
19.6.5. Financial
Analysis
19.6.6. SWOT
Analysis
19.6.7. Business
Strategies
19.7. F.
Hoffmann-La Roche Ltd
19.7.1. Company
Details
19.7.2. Company
Overview
19.7.3. Product
Offerings
19.7.4. Key
Developments
19.7.5. Financial
Analysis
19.7.6. SWOT
Analysis
19.7.7. Business
Strategies
19.8. GlaxoSmithKline
plc.
19.8.1. Company
Details
19.8.2. Company
Overview
19.8.3. Product
Offerings
19.8.4. Key
Developments
19.8.5. Financial
Analysis
19.8.6. SWOT
Analysis
19.8.7. Business
Strategies
19.9. Johnson
& Johnson Services, Inc
19.9.1. Company
Details
19.9.2. Company
Overview
19.9.3. Product
Offerings
19.9.4. Key
Developments
19.9.5. Financial
Analysis
19.9.6. SWOT
Analysis
19.9.7. Business
Strategies
19.10. Merck
& Co., Inc.
19.10.1. Company
Details
19.10.2. Company
Overview
19.10.3. Product
Offerings
19.10.4. Key
Developments
19.10.5. Financial
Analysis
19.10.6. SWOT
Analysis
19.10.7. Business
Strategies
19.11. Novartis
AG
19.11.1. Company
Details
19.11.2. Company
Overview
19.11.3. Product
Offerings
19.11.4. Key
Developments
19.11.5. Financial
Analysis
19.11.6. SWOT Analysis
19.11.7. Business
Strategies
19.12. Pfizer
Inc.
19.12.1. Company
Details
19.12.2. Company
Overview
19.12.3. Product
Offerings
19.12.4. Key
Developments
19.12.5. Financial
Analysis
19.12.6. SWOT
Analysis
19.12.7. Business Strategies
19.13. Other
Industry Participants
20. Key
Findings
Note: This ToC is tentative
and can be changed according to the research study conducted during the course
of report completion.
**Exclusive for Multi-User and
Enterprise User
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
